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Abstract 
Fusion of critically short or damaged telomeres is associated with the genomic rearrangements that support malignant 
transformation. We have demonstrated the fundamental contribution of DNA ligase 4-dependent classical non-
homologous end-joining to long-range inter-chromosomal telomere fusions. In contrast, localised genomic 
recombinations initiated by sister chromatid fusion are predominantly mediated by alternative non-homologous end-
joining activity that may employ either DNA ligase 3 or DNA ligase 1. In this study, we sought to discriminate the 
relative involvement of these ligases in sister chromatid telomere fusion through a precise genetic dissociation of 
functional activity. We have resolved an essential and non-redundant role for DNA ligase 1 in the fusion of sister 
chromatids bearing targeted double strand DNA breaks that is entirely uncoupled from its requisite engagement in 
DNA replication. Importantly, this fusogenic repair occurs in cells fully proficient for non-homologous end-joining and is 
not compensated by DNA ligases 3 or 4. The dual functions of DNA ligase 1 in replication and non-homologous end-
joining uniquely position and capacitate this ligase for DNA repair at stalled replication forks, facilitating mitotic 
progression.  
Introduction 
DNA ligase I (LIG1) is one of three identified human DNA ligases involved in multiple essential intracellular pathways 
(1,2). Whilst DNA ligase 3 (LIG3) and 4 (LIG4) have long been ascribed functions in non-homologous end-joining 
(NHEJ) repair (3), LIG1 has conventionally been associated with DNA replication (4-7). During the synthesis (S) phase 
of the mitotic cell cycle, the genome is replicated such that it can be partitioned equally amongst the progeny during 
the mitotic (M) phase. Leading and lagging strands of the double helix are differentially synthesised, with the nascent 
DNA derived from the lagging strand is produced as a series of short (100-300 nucleotide) Okazaki fragments (8) that 
require reassembly by LIG1. Consequently, LIG1 function is intimately linked with proliferative capacity (9) and its 
upregulated expression has been documented in human cancers (10). Intriguingly, mutations that compromise LIG1 
activity are also affiliated with cancer (11-13). Specifically, a patient presenting with developmental delays, immune 
deficiency and lymphoma was identified as having compound heterozygous mutations in LIG1 that severely reduced 
functional capacity. Fibroblasts derived from this patient demonstrated a range of DNA processing defects, including 
delayed ligation of replication intermediates, replication fork errors, enhanced sensitivity to DNA damaging agents (14) 
and hyperactivation of sister chromatid exchanges (15). Subsequent research has positioned LIG1 at the interface of 
interdependent DNA processing and repair pathways, including long-patch base-excision repair (LP-BER) (16), 
nucleotide excision repair (NER) (17), mismatch repair (MMR) (18) and, more recently, non-homologous end-joining 
(NHEJ) (19-21). Furthermore, advances in high-resolution molecular exploration of nucleic acid metabolism have 
delineated an ever-growing complexity of pathway interactions and defined novel subcategories of DNA repair in 
which LIG1 may also be pivotal (22). Collectively, these studies highlight the critical importance of this ligase in the 
DNA repair processes that safeguard genome integrity. 
 
For intelligently targeted therapeutic intervention (23), it is imperative to achieve clear separation of function between 
the DNA ligases and to more precisely understand the diversity, hierarchy and restrictions associated with the 
processes they coordinate. Notably, LIG3 and LIG1 appear functionally interchangeable in some experimental models 
(20,24-27) and genetic targeting has revealed a redundancy that permits viability with the solitary absence of either 
enzyme (28,29). The catalytic core of LIG1 and LIG3 is highly-conserved, suggesting that diversification of function is 
conferred by the unique N- and C-termini of the respective ligases and the particular protein mediators with which they 
interact (1). Intracellular temporal and spatial segregation of LIG1 and LIG3 (30) may reinforce functional disjunction 
and subtle differences in ligation kinetics and avidity (31,32) may dictate pathway selection under competitive 
conditions (33). Importantly, we have already documented a non-redundant role for LIG3 in the specialised DNA repair 
activity that permits cellular escape from a telomere-driven crisis (34). Thus, whilst LIG1 and LIG3 may have 
overlapping functional spectra, it is apparent that they also independently-regulate distinct processes. 
 
Telomere fusions represent a mutagenic DNA repair response to the recognition of shortened or damaged and 
deprotected chromosome ends as double-strand breaks (DSBs). The recombination of sister chromatid or 
heterologous chromosomal telomeres is mediated by NHEJ to produce dicentric chromosomes that can precipitate 
global genomic instability through progressive breakage-fusion-breakage cycles or more acute genetic fragmentation 
under the pressure of persistent mitosis (35,36). Fusions are rare in normal proliferating or senescent cells but can be 
detected with increasing frequency during crisis or in response to targeted DSBs (21,37). Significantly, these events 
have been reported in several malignancies in association with oncogenic transformation (38-40). The conspicuous 
emergence of telomere fusions and the express involvement of NHEJ components in their formation presents an 
unparalleled forum within which to rigorously investigate the relative activities of distinct DNA ligases. We formerly 
uncovered the potential engagement of LIG1 in telomere fusions that arise in absence of operational LIG3- and LIG4-
mediated alternative and classical NHEJ (A-NHEJ and C-NHEJ), respectively (21). By targeting a DSB to a specific 
telomere-proximal sequence, we were able to induce and perform the detailed molecular characterisation of a 
diversity of inter- and intra-chromosomal telomere fusions in cells differentially compromised for DNA repair. Although 
inter-chromosomal fusions were rarely recovered from cells lacking both LIG3 and LIG4, we determined an 
unexpected proficiency of these LIG3-/-:LIG4-/- cells for intra-chromosomal sister chromatid fusions that implicated the 
remaining ligase, LIG1, as being competent and sufficient to effect these particular telomere recombinations.  
 
In this study, we have exploited this bespoke DSB-induced telomere fusion strategy to confirm and further resolve the 
precise requirement for LIG1 in sister chromatid telomere fusion events that precede chromosome condensation and 
partition of the genome in mitosis. These studies demonstrate that LIG1 is critically employed in DNA repair at specific 
stages of the cell cycle when homology-dependent recombination (HDR) activity is incompatible with the coordinated 
resolution of chromosomal damage (41-44) and viable cytokinesis (45). 
Materials and Methods  
Cell culture  
All cells were routinely cultured at 37°C in 5% CO2, screened for the absence of mycoplasma and authenticated by 
functional or expression assays appropriate to their specific genetic backgrounds.   
HCT116 cell lines were cultured in McCoy's 5A medium supplemented with 10% (v/v) fetal calf serum, 1 x105 IU/l 
penicillin, 100 mg/l streptomycin, and 2 mM glutamine. Antibiotic selection agents were also added as required for 
long-term cultures (1 µg/ml puromycin for LIG1-/flox:CreERt2, 1 µg/ml puromycin and 2.5 µg/ml G418 for the LIG3-/-:LIG4-/-
:LIG1-/flox:CreERt2). Single cell suspensions were stained with 30 µg/ml acridine orange and 100 µg/ml DAPI (4′,6-
Diamidine-2′-phenylindole dihydrochloride) to count viable cells and determine mean cell diameters using the 
Chemometec NC-3000 image cytometer. 
Translocation of the CreERt2 transgenic fusion protein was achieved by an 18 to 24 hr treatment with 1 µM 4-OHT (4-
Hydroxytamoxifen; Sigma H6278) diluted 1/10000 with supplemented McCoy’s 5A from a 1 mg/ml stock in methanol 
for application to cells. Methanol carrier controls were prepared using the same 1/10000 dilution with medium. 
Construction of LIG1-/flox:CreERt2 HCT116 cell line 
Cre recombinase loxP recognition sites (illustrated as filled arrowheads in Supplementary Figure 1a) were introduced 
flanking exon 23 of human LIG1 in a wild-type (WT) HCT116 cell line using the adeno-associated viral promoter 
trapping vector (pAAV-LIG1-SEPT). Sequential rounds of targeting and Cre recombination resulted in a single clone 
harbouring one recombined LIG1 deletion allele and one ‘floxed’ allele retaining the flanking loxP sites (HCT116 LIG1-
/flox). A Cre-oestrogen receptor transgene (CreERt2) was subsequently added via lentiviral integration, permitting 
conditional recombination of the remaining LIG1 allele at exon 23 by a transient 20 to 24 hr exposure to 1 µM 4-OHT 
to produce a biallelic functional deletion of LIG1. Consequently, any resultant LIG1 transcripts lack sequence encoding 
both the C-terminal DNA-binding and ligase domains. Correctly targeted clones were identified by PCR screening of 
genomic DNA. Validation of the Cre-mediated recombination of the single intact LIG1 allele was performed by 
genomic PCR using primers designed to amplify and distinguish ‘floxed’ and deleted alleles: LIG1_LOXP_SF 5′-
ATGTCCTGTTCGCCTCAC-3′; LIG1_LOXP_SR2 5′-AGGGTACACAGTGGAGTC-3′. Representative analyses are 
shown in Figure 1a. Confirmation of reduced LIG1 mRNA and protein expression following 4-OHT-induced allelic 
recombination is shown in Figures 1b, 1c and Supplementary Figures 1b, 1c. Figures 1e, 1f and Supplementary 
Figures 1d-1f display the functional cell cycle arrest achieved upon 4-OHT-induced LIG1 deletion. 
 
 
Construction of a LIG3-/-:LIG4-/-:LIG1-/flox:CreERt2 HCT116 cell line 
In order to generate a LIG1 conditional knockout in HCT116 LIG3-/-:LIG4-/- double knockout cells that maintain 
essential expression of mitochondrial LIG3 (21), CRISPR/Cas9-mediated gene targeting was used (Supplementary 
Figure 4a). Briefly, a double strand DNA (DSB) in exon 23 of the LIG1 gene was generated by Cas9 using the sgRNA 
5′-GTAGGTGGCATCAACATCCA-3′. This was accomplished using a CRISPR/Cas9-t2A-GFP co-expression vector 
(PX458) along with a double stranded rAAV plasmid donor containing homologous sequences 5′ and 3′ to a ‘floxed’ 
LIG1 exon 23 bearing a silent mutation that interrupts the PAM sequence for the gRNA. Upon screening 21 candidate 
clones, one (#15) was identified that had a single correctly ‘floxed’ LIG1 allele with the other allele acquiring a deletion 
within exon 23 that resulted in a null allele. To generate the conditional biallelic LIG1 null line, a PiggyBac CreERt2 
Puro expression vector was randomly integrated by co-transfection with a PiggyBac transposase expression vector. 
The transfected cells were selected using 1 µg/ml puromycin and a total of 5 puromycin-resistant clones (including 
C15-5 and C15-9) were further characterized. Initial functional complementation was demonstrated by culturing the 
cells in the presence or absence 20 nM 4-OHT for 24 hr, followed by 3 days in 10 nM 4-OHT before extraction of 
genomic DNA for confirmation by genomic PCR. Validation of the Cre-mediated recombination of the single intact 
LIG1 allele was performed by genomic PCR using primers designed to amplify and distinguish ‘floxed’ and deleted 
alleles: LIG1 Ex22_F 5′-CTGGAGCAGTCAGTGAAAGG-3′; LIG1 Int23_R 5′-GGCTGTTCTCCATCAGAACTC-3′. In 
subsequent experiments, Cre-mediated LIG1 recombination was induced by a transient 20 to 24 hr exposure to 1 µM 
4-OHT to produce a biallelic functional deletion of LIG1. Representative analyses are shown in Supplementary Figure 
4c(ii) and 4d(i). Supplementary Figure 4c(iii) demonstrates the reduction in LIG1 mRNA expression and 
Supplementary Figure 1c illustrates the consequent diminution in LIG1 protein achieved upon 4-OHT-induced LIG1 
deletion in the LIG3-/-:LIG4-/- background. Figure 5a confirms the functional cell cycle resulting from the LIG1 depletion. 
Inhibitors 
The LIG1 inhibitor, L82, was a kind gift of Dr. Alan E. Tomkinson and Dr. Tim Howes of the University of New Mexico, 
USA (23,46). L82 was reconstituted to 10 mM using DMSO and stored in aliquots at -80°C. Stock solutions were 
further diluted to 5 and 50 µM in cell culture medium for use in the experiments indicated. 
For enrichment of cells in the G2 cell cycle phase, cultures were treated with the microtubule disruptor, nocodazole 
(Sigma M1404) at 50 ng/ml. Serial dilutions were prepared in PBS and supplemented medium from a 1 mg/ml stock in 
DMSO. Carrier controls were prepared using the same serial dilutions of DMSO. Cells were typically pre-treated for 18 
to 24 hr before nucleofection experiments. 
For enrichment of cells in the G1 cell cycle phase, cultures were treated with the iron chelator DNA replication 
inhibitor, L-mimosine (Sigma M0253) at 200 µM diluted in supplemented culture medium. Cells were typically pre-
treated for 18 to 24 hr before nucleofection experiments. 
Confirmation of inhibition was confirmed by cell cycle analyses using a Chemometec NC-3000 image cytometer or 
Accuri C6 flow cytometry to detect cellular DNA content and proportions of G2/M mitotic cells. More than 5000 events 
were routinely collected for analyses of sample populations. 
Where experiments required LIG1 recombination of G2 phase cells, cells were treated with nocodazole for 4 to 6 hr 
before addition of 4-OHT and continued culture for a further 20 hr prior to nucleofection. Post-nucleofection, cells were 
re-treated with cell cycle inhibitors after a 30 min recovery period and re-dosed in fresh medium after 24 hr for 
samples to be harvested at 48 hr. 
Cell cycle analyses 
Cell cycle analyses of fixed cells were performed using either the Accuri C6 flow cytometer or the Chemometec NC-
3000 image cytometer depending on experimental design. 
For NC-3000 assays, cells were fixed with 70% ethanol for 2 to 24 hr at -20°C prior to permeabilisation with 0.1% 
Triton X-100 and incubated with 1 µg/ml DAPI DNA stain for 5 min at 37°C. Exported FCS3 files were processed 
using Flowing software to delineate cell cycle phases and determine proportions of cells in each fraction. 
For Accuri C6 flow cytometry, cells were fixed with 1% formaldehyde for 10 min at 37°C before being permeabilised 
with methanol (90% final concentration) at -20°C for 2 to 24 hr. Cells were pelleted and washed with PBS before being 
incubated with 50 µM DRAQ5TM or 125 ng/ml DAPI DNA staining for 30 to 60 min in the dark at room temperature. 
More than 5000 events were collected with the Accuri C6 flow cytometer and cell cycle distributions were determined 
from histograms generated using the Accuri C6 analysis software. 
Detection of pHH3- and gH2AX-expressing populations by flow cytometry 
To determine the fractions of actively dividing G2/M mitotic cells, the Cell Signaling Technology rabbit monoclonal 
antibody, anti-phospho-histone H3 (Ser10) clone D2C8, conjugated with Alexa Fluor® 488 or Alexa Fluor® 647 was 
used at 1/50 dilution for < 1x106 cells. 
To measure the DNA damage response, the BD Biosciences mouse monoclonal antibody, (N1-431) anti-gH2AX 
PerCP-Cy5 (BD564718), was used at 1/20 dilution for < 1x106 cells. 
Cells were harvested 24 hr post-nucleofection and single cell suspensions were fixed with 1% formaldehyde and 
permeabilised with methanol to 90% final volume for 2 to 24 hr at -20°C. Samples were blocked with either 5% rabbit 
or 2% foetal calf serum in PBS, then washed by centrifugation and incubated with antibodies indicated for 45 min in 
the dark at room temperature. Detection of expressing cells (signal intensity threshold set at 104) was carried out 
using the Accuri C6 flow cytometer collecting > 5000 events. 
Flow cytometry of isolated nuclei  
To confirm the nocodazole-induced increase in cellular DNA content was due to cytokinesis block rather than 
formation of multinuclear or fused cells, analysis of DNA content in isolated nuclei was performed by flow cytometry. 
Nuclei were isolated according to the protocol established by Zeng et al. (47). Briefly, 1x106 cells were pelleted and 
resuspended in PBS for accurate assessment of mean cell diameter and viability using the Chemometec NC-3000 
image cytometer ahead of nuclear isolation. Cells were lysed in buffer containing 10 mM Tris-HCl pH7.4, 10 mM NaCl, 
3 mM MgCl2 and % IGEPAL CA-630 on ice for 20 min. Liberated nuclei were pelleted by centrifugation at 500 x g for 
20 min at 4°C. Completion and purity of lysis and extraction were verified by determination of expected reduction in 
particle diameter and viability using elevated concentrations of acridine orange (80 µg/ml) for more sensitive detection 
of smaller nuclei using the NC-3000. Purification was repeated by additional lysis or filtration through 20 µm sterile 
CellTrics filters where necessary. 
Purified nuclei were fixed with 1% formaldehyde and permeabilised with methanol at 90% final concentration for 24 hr 
at -20°C before antibody staining. Single nuclei suspensions were serum-blocked (2% FCS) and incubated for 30 to 
45 min in the dark at room temperature with 1/50 dilution of Cell Signaling Technology rabbit monoclonal antibody 
anti-phospho-histone H3 (Ser10) clone D2C8 conjugated with Alexa Fluor® 488. Cells were washed in PBS and 
counterstained with 50 µM DRAQ5TM for 30 min in the dark at room temperature. Detection of phospho-histone H3 
(pHH3)-expressing cells (signal intensity threshold set at 104) and determination of DNA content was carried out using 
the Accuri C6 flow cytometer collecting > 5000 events.  
17p and 16p/21q (21q) subtelomere TAL effector nucleases  
TAL Effector Nucleotide Targeter 2.0 software (Cornell University) (48) was used to design TAL Effector Nuclease 
(TALEN) pairs to cleave human subtelomeric sequence at targeted single nucleotide locations. One pair (17p TLN) 
was designed to target the unique 17p subtelomere sequence 32 bp centromeric to start of the telomere repeat array. 
One pair (21q TLN) was designed to target sequence 1.5 kb from the start of the telomere repeat arrays of the 
homologous 16p- and 21q-related telomere families. TALEN pairs and surrogate reporters for targeting validation 
were custom-synthesised by LabOmics S.A. and endotoxin-free transfection-quality plasmid preparations were 
purified from Stbl3 competent cells (Invitrogen) using Nucleobind Xtra Midi Plus kits (Macherey-Nagel). Plasmid 
identity was confirmed by XbaI restriction enzyme mapping and Sanger DNA sequencing.  
17p and 16p/21q subtelomere TALEN transfections 
Subconfluent (50 to 80%) HCT116 cells were nucleofected with 2.5 µg of each 17p subtelomere-specific (17p TLN) or 
16p/21q family subtelomere-specific (21q TLN) TALEN plasmid in batches of 1x106 cells/cuvette in 100 µl 
supplemented nucleofection mix (Lonza SE Cell Line Kit L) using the Amaxa 4D nucleofector program DS-138. 
Following 10 min recovery post-nucleofection in unsupplemented RPMI at 25°C and 15 min incubation in complete 
McCoy’s 5A at 37°C, transfection replicates were pooled for co-culture to eliminate inter-sample variation. Cells were 
plated into 6 or 12 well tissue culture plates and supplemented with the requisite experimental cell cycle inhibitors. 
Selection antibiotics and 4-OHT were not re-applied post-nucleofection. Cells were harvested at 24 (t24) or 48 (t48) hr 
post-nucleofection, with re-application of cell cycle inhibitors at the 24 hr time point to ensure cell cycle arrest was 
sustained for 48 hr. Harvested cells were pelleted and counted for use in downstream analyses as indicated.   
Control (no DNA) or GFP plasmid transfections were performed in each experiment to determine transfection 
efficiency as well as the background level of DNA damage and spontaneous telomere fusion. 
Determination of transfection efficiency  
1x106 cells were nucleofected with 1 µg of a GFP expression plasmid (Lonza pmaxGFP) and harvested 24 hr later for 
analysis of GFP expression in viable cells using the Chemometec NC-3000 image cytometer. Representative single 
cell samples were aliquoted and supplemented with Hoechst 33342 at a final concentration of 10 μg/ml. Samples 
were incubated for 15 min at 37°C before propidium iodide was added to a final concentration of 10 μg/ml and GFP 
expression in viable cell populations was measured and extrapolated to the sample bulk as a transfection efficiency 
percentage.  
RNA extraction and RT-PCR: 
Total RNA was extracted using the Analytik Jena InnuPrep RNA Mini Kit with elution into nuclease-free water. RNA 
concentrations were measured using a nanodrop spectrophotometer and 1 µg purified RNA was reacted in the 
presence or absence of reverse transcriptase using the Applied Biosystems High Capacity cDNA RT kit to distinguish 
true cDNA amplification from residual genomic DNA template. Equal volumes of cDNA were subjected to 32 cycle RT-
PCR using intron-spanning primers unique to each experimental tester gene and an annealing temperature of 60°C. 
RT-PCR primers used in this study and the relative amplicon sizes are listed as Supplementary Table 1. 
Amplicons were resolved by agarose (1% weight/volume) gel electrophoresis with ethidium bromide DNA staining and 
images were captured using a Vilbert Lourmat Ebox VX2 gel documenter. 1 kb and 100 bp DNA ladders were 
routinely run for sizing of amplicons. Quantification of amplicon signal intensity with local background correction was 
performed using ThermoFisher MyImageAnalysis software and normalised to values calculated for the constitutively-
expressed Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta (YWHAZ) control gene 
within the same samples. Normalised gene expression values are presented as tester/YWHAZ signal intensity. 
Western blotting 
HCT116 wild-type (WT), LIG3-/-:LIG4-/-, LIG1-/flox:CreERt2, parental clone C15 LIG3-/-:LIG4-/-LIG1-/flox and LIG3-/-:LIG4-/-
:LIG1-/flox:CreERt2 clones C15-5 and C15-9 were cultured in the presence of 1 µM 4-OHT or methanol (MeOH) carrier 
control for 24 hr before 2x106 cells of each sample were pelleted and snap frozen for protein extraction. Cells were 
lysed with RIPA buffer supplemented with protease inhibitors and proteins harvested by centrifugation. Lysates were 
quantified using Sigma Advanced Protein Assay reagent in comparison with a BSA protein standard curve read at 
OD600. 10 µg each sample lysate was boiled in 6X Laemmli's loading dye with β-mercaptoethanol and run on a 7.5% 
Tris-glycine gel for 80 min at 100V. Transfer to PVDF membranes was at 70V for 90 min. Membranes were blocked in 
5% milk-TBST for 1 hour at room temperature before incubation with primary antibodies diluted in 5% milk-TBST at 
4◦C overnight with agitation. Primary antibodies used in this study were: GeneTex rabbit polyclonal anti-C-terminal 
human LIG1 antibody (GTX102936) diluted 1/1000, Abcam mouse monoclonal anti-human LIG1 (amino acids 1-919) 
antibody [10H5] (ab615) diluted 1/3000 and Sigma rabbit polyclonal anti-C-terminal actin fragment antibody (A2066) 
diluted 1/1000. Amersham ECL secondary HRP-conjugated anti-rabbit (NA934) or anti-mouse (NA931) antibodies 
were used, as appropriate, at 1/10000 dilution in 5% milk-TBST with incubation for 1 hr at room temperature. Pierce™ 
ECL Plus Western Blotting Substrate was used for signal detection via exposure to X-ray film. Membranes were 
stripped using a mild stripping glycine-SDS protocol at room temperature before repeat blocking and immunoprobing. 
Total protein loading was visualised post-immunoprobing by staining membranes with 0.1% liquid Indian ink (Winsor 
and Newton) -PSBT overnight. Quantification of signal volume (intensity) from scanned images was performed using 
ThermoFisher MyImageAnalysis software. A composite normalisation method was employed to calculate the fold 
change in aggregated LIG1 protein expression in 4-OHT-treated compared with MeOH-treated samples corroborated 
using two independent primary antibodies raised in different species to confirm antigen specificity. Sample protein 
equivalence was assessed by dual quantification of actin housekeeping and constitutive protein loading signal 
determined by immunoprobing and membrane staining. 
Genomic DNA extraction 
Total genomic DNA from HCT116 was extracted using Sigma GenEluteTM Mammalian Genomic DNA Miniprep Kits 
and eluted in nuclease-free water. DNA was quantified using a nanodrop spectrophotometer to confirm a consistent 
purity and DNA yield for use in genomic PCR, telomere fusion PCR and sequencing reactions. 
Genomic PCR 
Cre-mediated recombination of LIG1 exon 23 in LIG1-/flox:CreERt2 and LIG3-/-:LIG4-/-:LIG1-/flox:CreERt2 HCT116 cells was 
routinely assessed by genomic PCR using the primers detailed in Supplementary Table 1 and 100 to 200 ng sample 
genomic DNA. Defined positive control genomic DNA and negative control water blanks were included in every 
experiment.  
Amplicons were resolved by agarose (1% weight/volume) gel electrophoresis with ethidium bromide DNA staining and 
images were captured using a Vilbert Lourmat Ebox VX2 gel documenter. 1 kb and 100 bp DNA ladders were 
routinely run for sizing of amplicons. Quantification of amplicon signal intensity with local background correction was 
performed using ThermoFisher MyImageAnalysis software. 
Telomere fusion PCR and Southern hybridisation 
Telomere fusion amplicons were generated from sample input genomic DNA (100 ng unless otherwise indicated ) by 
multiplex long-range PCR using primers targeting the 17p, XpYp and 21q family of homologous telomeres (17p6, 
XpYpM and 21q1 primers, respectively; detailed in Supplementary Table 1) (36,49). This resulted in mixed pools of 
fusion amplicons with divergent molecular weights. A 2.9 kb constitutive amplicon band of known sequence identity is 
also detected with the 21q probe, but excluded from all fusion amplicon analyses. For standard experiments, 3 or 4 
individual replicate reactions were typically resolved by 0.5% TAE agarose gel electrophoresis for detection on 
Southern blots using radiolabelled telomere-adjacent probes specific for each telomere end. To estimate telomere 
fusion frequency in each sample, the number of resolved non-constitutive fusion amplicons revealed by Southern 
blotting was summarised and divided by the mass in ng of input DNA since ploidy was variable amongst samples. 
Fusion frequencies are therefore expressed as events per ng rather than per diploid genome.  
Illumina MiSeq and HiSeq 2000 paired-end sequencing of 17p telomere sister chromatid fusions  
17p TALEN-induced sister chromatid telomere fusions were amplified from G2-arrested HCT116 LIG1-/flox:CreERt2 cells 
harvested 24 hr post-nucleofection in 250 telomere fusion PCR replicates for Illumina MiSeq 300 cycle 150 bp paired-
end sequencing. Random PCR wells were selected for cross-checking validation prior to the replicates for each 
sample being pooled and purified using Agencourt AMPure XP magnetic beads with elution in nuclease-free water. 
Aliquots of each sample were taken pre- and post-purification for a comparative assessment and to check purification 
efficiency. Sequencing of the G2-arrested LIG3-/-:LIG4-/- fusions was performed in collaboration with the Wales Gene 
Park using the Nextera XT sample prep kit.  
Illumina HiSeq 2000 paired-end sequence data for 17p TALEN-induced telomere fusions derived from unsynchronised 
LIG3-/-:LIG4-/- cells at 48 hr post-nucleofection (85 fusion PCR replicates) and LIG3-/- cells at 48 and 120 hr (85 and 
170 fusion PCR replicates, respectively) post-nucleofection was collected and explored in a former study (21). New 
analyses of the unsynchronised LIG3-/-:LIG4-/- 17p sister chromatid telomere fusion-mapping reads pertaining to the 48 
hour time point only were conducted for the current study, in contrast with the pooled analyses of all 48 hour and 120 
hour data in the previous study (21).  
Paired-end sequence read quality of each sample was checked prior to analysis using the Fastqc (v0.11.2; 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) software package alongside in-house tools that assessed 
mapping success and insert size-range. All reads were trimmed and filtered with Trimmomatic (version 0.30 (50)) to 
remove sequencing adaptors and over-represented primer sequences. All scripts developed for the mapping and 
analysis of sequence data can be found on GitHub at 
https://github.com/nestornotabilis/GenomeResearch_2016_scripts.  
Alignment of sequence reads, clone sequences and assembly contigs was performed with BWA-MEM version 0.7.4, 
arXiv:1303.3997). All mappings were performed with the default parameters save for the addition of the -M flag to 
mark shorter split hits as secondary for later filtering. Unless otherwise stated, all manipulations of the mapped outputs 
were performed using SAMtools version 0.1.19 (51). Sister chromatid 17p telomere fusion events were identified as 
discordant read-pairs mapping to the same strand in the same orientation towards the telomere indicative of head-to-
head juxtapositions. Reads were first mapped to the 17p subtelomeric sequences and the SAMtools view command 
(samtools view -bF316) was applied to each output to filter for mapped paired-end reads where both the R1 and R2 
tags were orientated on the same strand and oriented towards the telomere. A SAMtools mpileup command (samtools 
mpileup -ABd100000) was next applied to the filtered output to extract per-base coverage data. Indexed BAM files for 
all sample intra-chromosomal mapped and filtered read pairs were prepared for visualization in the Broad Institute 
Integrative Genomics Viewer (52). 
Junction analyses 
Mapped 17p sister chromatid telomere fusions were analysed in high-resolution by BLAST alignment to define 
junction and recombination characteristics. The incidence of microhomology, insertions and resection from each 
individual fusion junction was determined manually. Microhomology was defined as > 1 bp overlap in nucleotide (nt) 
usage in both fusion partners and events were subsequently categorised in terms of frequency, as well as the 
numbers of nt involved at each junction. Insertions (< 50 bp) between apposed fusion partners were categorised as 
templated if > 2 nt localised duplication or sequence similarity could be determined, or untemplated if unidentified by 
BLASTN mapping to any reference sequences. Deletion was measured back from the telomere-proximal 17p TALEN 
target site at 3024 bp from the 3′ terminal end of the 17p6 fusion amplifying primer. 17p chromatids extending beyond 
the TALEN cut site (either uncut or extended post-cleavage) were assigned a deletion value of 0.  
Quantification of nucleotide incorporation error rate  
Illumina sequencing read pairs mapping to the 17p subtelomere were extracted and BLAST aligned to this reference 
to reveal nucleotide (nt) changes in the ‘centromeric’ (centromere-telomere orientation of single fusion amplicon 
sequenced 5′ - 3′) and ‘telomeric’ (telomere-centromere orientation) reads comprising each sister chromatid fusion 
event. The numbers of nt variant from the 17p subtelomere reference were normalised to read length adjusted for the 
exclusion of soft-clipped portions to generate the error rate/kb. All reads longer than 30 bp were included, but three 
SNP common to unsynchronised read pairs were excluded from the analysis. 
Statistical analyses  
All statistical analyses, including one- and two-tailed T-tests, Mann-Whitney U-tests and Kruskal-Wallis ANOVA tests 
were performed using GraphPad Prism 6 and GraphPad QuickCalcs. Appropriate tests were selected according to 
whether data were collected as paired or independent experimental samples, whether data distributions were 
Gaussian or skewed and whether variance between comparators was equal. One-tailed T- and U-tests were applied 
where required to specifically assess a pre-defined direction of the biological effect under consideration. For all tests, 
a P value of less than 0.05 was considered statistically significant. 
Data Access  
BAM files containing trimmed and filtered data for the unsynchronised LIG3-/-:LIG4-/- HCT116 sample are available in 
the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-3811. 
BAM files containing trimmed and filtered data for the G2-arrested LIG3-/-:LIG4-/- HCT116 sample are available as a 
NCBI Bioproject (www.ncbi.nlm.nih.gov/bioproject), accession number PRJNA480939. 
 
Results 
Depletion of LIG1 causes cell cycle arrest and altered morphology 
We have reported the recovery of sister chromatid telomere fusions from HCT116 cells dually-deficient for the 
alternative- (A-NHEJ) and classical-non-homologous end-joining (C-NHEJ) nuclear-localised DNA ligases, LIG3 and 
LIG4, respectively (LIG3-/-:LIG4-/-) (21). The parity of these events with fusions amplified from cells individually 
deficient in either LIG3 or LIG4 suggested a redundancy amongst ligases for sister chromatid telomere fusion and led 
us to propose a role for LIG1 in the context of otherwise compromised C-NHEJ and A-NHEJ repair. To more precisely 
define the activity of LIG1 in sister chromatid telomere fusions, we utilised recombinant adeno-associated virus-
mediated gene targeting to construct a heterozygous HCT116 LIG1-/flox:CreERt2 cell line (L1-/fx:Cre) in which one allele had 
been inactivated and the other allele was 'floxed' by the introduction of loxP sites flanking exon 23 of the LIG1 gene 
(Supplementary Figure 1a). Loss of exon 23 impedes the DNA binding function of LIG1 so that homozygous LIG1-/- 
cells could not be propagated owing to the fundamental role of LIG1 in DNA replication. Exon 23 of the remaining 
LIG1 allele was deleted by conditional activation of a Cre-oestrogen receptor fusion protein (CreERt2) with 4-
hydroxytamoxifen (4-OHT) for 24 hr, permitting fine temporal control over cellular depletion of functional LIG1. 
Appropriate allelic excision in 4-OHT-treated and not methanol (MeOH) carrier-control-treated cells was confirmed by 
comparative amplification of 'floxed' and deleted alleles by genomic PCR ahead of functional analyses (Figure 1a). 
Two independent HCT116 LIG1-/flox:CreERt2 conditional recombination clones were generated from the original LIG1-/flox 
clone. For simplicity and consistency, data relating only to LIG1-/flox:CreERt2 Clone 1 is presented in this study. 
Induced recombination of the second LIG1 allele resulted in a reproducible 2-fold reduction (P = 0.0226) in LIG1 
mRNA expression within 24 hr (Figure 1b, Supplementary Figure 1b). Recombination-associated down-regulation of 
LIG1 expression was determined under conditions of chemically-induced G1 (mimosine) and G2 (nocodazole) cell 
cycle arrest (verified in Supplementary Figure 1b(ii)), as well as in unsynchronised cells, confirming the suitability of 
the model for the investigation of LIG1 ligase function in NHEJ, unrestricted by cell cycle phasing. In contrast, 
expression of LIG3 and LIG4 mRNA was not substantially altered by the deletion of LIG1 (Figure 1c), thus permitting 
separation of ligase functions. Using primers to detect mRNA transcripts derived from distinct exons of LIG1, we were 
able to confirm reduced expression of LIG1 both 3′ and 5′ of the Cre recombination locus at exon 23 (Supplementary 
Figure 1b(iii) in unsynchronised and G2-arrested cells in response to 4-OHT treatment. Conversely, transcripts 
corresponding to exons encoding N-terminal protein domains were detected at similar levels in 4-OHT-treated and 
untreated cells arrested in G1 conditions for 24 hr. These results suggest a degree of LIG1 transcriptional feedback 
regulation following deletion of the catalytic and DNA binding domains critical for DNA replication and progression 
through cell cycle S-phase.  Cells arrested prior to S-phase in G1 evade this replication stress engendered by ligase-
incompetent LIG1 and maintain active transcription of this gene, albeit lacking exons encoding ligase functional 
domains following Cre-mediated recombination.   
Significant reductions in LIG1 protein expression were also measured exclusively in cells harbouring a 'floxed' LIG1 
allele within 24 hr of 4-OHT addition (Supplementary Figure 1c), indicating that the impact of LIG1 deletion could be 
rapidly experienced within proliferating cells. Specifically, LIG1 expression was reduced 1.9-fold by 4-OHT-mediated 
LIG1 deletion in LIG1-/flox:CreERt2 cells compared with the stable expression in wild-type (WT) HCT116 (P = 0.0332). We 
were unable to measure expression levels of any N-terminal truncated LIG1 proteins in these experiments, although 
the decreases in mRNA derived from exons 4-5 (Supplementary Figure 1b(iii)) detected following exon 23 
recombination suggest the possibility of inter-dependent regulation. 
Over short-term experimental timescales, the LIG1 haploinsufficiency effected by the constitutively-deleted allele in 
untreated LIG1-/flox:CreERt2 clones did not significantly alter cellular growth rates (P = 0.743, Figure 1d) in comparison 
with wild-type (WT) or LIG3-/-:LIG4-/- (L3-/-:L4-/-) HCT116 cells. In contrast, the phenotypic consequences of deleting the 
remaining LIG1 allele from HCT116 LIG1-/flox:CreERt2 cells were acute and compelling. At 24 hr post 4-OHT treatment, 
we determined a robust arrest in cell cycle progression of LIG1-depleted cells that manifested as an almost complete 
loss (11.8-fold reduction; P = 0.0044) of phospho-histone H3 (pHH3)-expressing G2/M phase mitotic cells (Figure 1e, 
Supplementary Figure 1d(i)) and an accumulation of tetraploid cells with > 4N DNA content (Figure 1f, Supplementary 
Figure 1d(ii)). LIG1-depleted cells exhibited a 2.22-fold increase (P < 0.001) in post-replicated populations at the 
expense of a 3-fold reduction (P < 0.001) in proportions with normal diploid (2N) DNA content (Figure 1f). The 4-OHT-
mediated cell cycle arrest was not reproducible in WT (Supplementary Figure 1d) and other DNA repair-deficient lines 
tested (Supplementary Figure 1e), indicating the effect was a specific consequence of LIG1 depletion and consistent 
with LIG1 being required for the efficient maturation of mitotic DNA replication intermediates (54). Ploidy increases 
were not caused by multinucleation since results using isolated nuclei (Supplementary Figure 1d(ii)) paralleled those 
obtained with whole cells (Supplementary Figure 1f). The expansion of cellular fractions with > 4N DNA content 
following LIG1 depletion reflects both the retarded lagging strand DNA synthesis and the contraction of populations 
advancing through subsequent rounds of cell cycle. 
In association with the increased DNA content of arrested LIG1-depleted cells, notable enlargement and altered 
adhesion properties were also observed (Supplementary Figures 1g, 1h). Whereas WT and LIG3-/-:LIG4-/- cells 
maintained an adherent and spindle-like morphology under 4-OHT treatment, the LIG1-/flox:CreERt2 cells were strikingly 
transformed from self-aggregating rounded cells to flattened cells with increased topical adhesion and trypsin 
resistance when the second LIG1 allele was deleted. This dramatic change in morphology in the absence of LIG1 was 
surprisingly even more prominent in cells pre-treated with nocodazole to induce a G2 cell cycle phase block 
(Supplementary Figure 1h). Nocodazole treatment was employed to potently arrest and enrich proportions of cells with 
> 4N DNA content (Supplementary Figure 1f), recapitulating the effects of 4-OHT-induced LIG1 deletion and 
permitting investigation of LIG1 function divorced from the influence of cell cycle progression. Importantly, nocodazole 
pre-treatment also stabilised the expression of LIG3 and LIG4 in response to 4-OHT, removing the potential for this 
variable to confound results (Figure 1c and Supplementary Figure 1b). As anticipated, WT, LIG3-/-:LIG4-/- and LIG1-
/flox:CreERt2 cells displayed enhanced mean cell diameters (captured in single cell suspension) under G2-arrest 
compared with their unsynchronised counterparts (WT; 1.21-fold, P = 0.002, LIG3-/-:LIG4-/-; 1.13-fold, P = 0.0003, 
LIG1-/flox:CreERt2; 1.10-fold, P = 0.0238) (Figure 1g). Even in the context of G2-arrest, the deletion of LIG1 from LIG1-
/flox:CreERt2 cells resulted in a significant supplementary increase in cell size (1.11-fold; P = 0.0412) that equated to a 
greater than 1.5 micron difference in mean cell diameter. Thus, LIG1 depletion likely impacts cytoskeletal interactions 
in addition to DNA replication, resulting in stalled cell populations with replicated 4N DNA content and altered 
morphology and adhesion properties.  
LIG1 depletion did not, however, result in any appreciable impairment of cell viability over longer term (7 days) culture 
(Supplementary Figure 1i). The patent alterations in cell morphology (Supplementary Figure 1i(i)) and size  (1.5-fold 
greater in 4-OHT-treated compared with MeOH-treated) (Supplementary Figure 1i(ii)) were exacerbated, whilst the 
depressed cell number (0.6-fold in 4-OHT-treated compared with MeOH-treated) (Supplementary Figure 1i(ii)) 
underscores the cytostatic impact of the LIG1 deletion evidenced in Supplementary Figure 1i(iii) and (iv).  
Interestingly, the reduced expression of senescence-associated genes, DPP4 (55) and HMGA2 (56), suggests that 
LIG1 depletion does not activate a global senescence program, whereas the moderate (1.2-fold) up-regulation of 
CDKN1A transcripts is indicative of increased DNA damage signalling in response to the ongoing replication stress 
(Supplementary Figure 1i(iv)). Hence, the morphological changes resulting from LIG1 depletion are likely associated 
with the onset of cellular quiescence (57), rather than senescence or apoptosis. 
 
LIG1 is absolutely required for sister chromatid telomere fusions 
We have developed a model for studying telomere fusions uncoupled from the selective pressure of telomere attrition 
and crisis (21). To discriminate the relative roles of DNA ligases in telomere fusions in this study, we employed a 
similar strategy using transient transfection of Transcription Activator-like Effector Nucleases (TALEN) designed to 
cleave precise subtelomeric locations at the unique 17p telomere or the 16p/21q families of homologous chromosome 
ends that consists of at least 19 distinct telomeres (36). The 17p TALEN recognition site is immediately adjacent to the 
telomere repeat array, whereas the 21q TALEN targets sequences common to the 16p/21q telomere families located 
~1.5 kb from the start of the canonical telomere repeats. Since LIG1-depletion resulted in a clear and durable cell 
cycle arrest and accumulation of G2 phase cells (Figure 1e, 1f, Supplementary Figures 1d-f), the exploration of 
TALEN-induced telomere fusions was performed in both unsynchronised cells and those arrested in G2 by 
nocodazole pre-treatment to homogenise this effect across all cell lines compared. G2 conditions were perpetuated 
post TALEN transfection so that both damage induction and repair occurred within a single phase of the cell cycle 
when sister chromatids were available as fusion substrates and without the incremental constraints of cytokinesis. 
Telomere fusions were detected by Southern hybridisation following single molecule long-range PCR (Figure 1h, 2a) 
using unidirectional 17p, XpYp and 21q family chromosome-specific primers (Supplementary Table 1) that yield 
amplicons only from covalently-linked fused or recombined chromosomes.  
Transfection with the 17p TALEN robustly induced 17p telomere fusions in MeOH carrier control-treated LIG1-
/flox:CreERt2 cells under both unsynchronised and G2-arrested conditions, as detected with a 17p subtelomere- but not 
with a 21q subtelomere-specific hybridisation probe (Figure 2a and a comparison with LIG1-expressing LIG3-/-:LIG4-/- 
cells shown in Supplementary Figure 2a). These fusions could be correspondingly amplified using a single 17p 
subtelomere primer, alone (Supplementary Figure 2b), consistent with originations in sister chromatid telomere fusion. 
In contrast to the MeOH carrier control-treated LIG1-/flox:CreERt2 cells, the LIG1-depleted cells demonstrated a 
remarkable and invariable loss of 17p TALEN-induced sister chromatid fusions under all conditions tested (Figure 2a 
and Supplementary Figure 2a and 2b). In unsynchronised LIG1-/flox:CreERt2 cells, 17p telomere fusion frequency was 
reduced more than 50-fold (P = 0.0313) by 4-OHT-mediated LIG1 deletion (Figure 2b, central bars), complementing 
the potent cell cycle inhibition observed (Figure 1e-f, Supplementary Figure 1d-f). However, 17p fusions were still 
13.2-fold lower in frequency (P = 0.0111) when LIG1 was depleted from cells already arrested in G2 phase (Figure 2b, 
far right bars), indicating additional cell cycle-independent consequences of the loss of this ligase. Whilst the 
transfection efficiency of LIG1-depleted cells was lower than for WT, LIG3-/-:LIG4-/- and carrier controls 
(Supplementary Figure 2c), adjusting fusion assay DNA input accordingly did not disclose latent fusions 
(Supplementary Figure 2d), so that the deficit is unconnected to assay efficiency at the limits of detection. 
Importantly, these results also indicate a lack of functional compensation in telomere fusion end-joining by LIG3 and 
LIG4 expressed by LIG1-/flox:CreERt2 cells (Figure 1c and Supplementary Figure 1i(iv)). Direct comparison of 17p fusion 
frequency in LIG3-/-:LIG4-/- cells that express only LIG1 (although maintaining expression of the essential 
mitochondrial-localised LIG3) (21) with LIG1-/flox:CreERt2 cells sufficient for all three ligases revealed no substantial or 
statistically significant difference (P = 0.4805, Figure 2c and Supplementary Figure 2a), affirming that LIG1, alone, is 
sufficient, as well as necessary for sister chromatid fusion. Fusion frequency was comparable between LIG1-
expressing unsynchronised and G2-arrested LIG1-/flox:CreERt2 cells (P = 0.1855, Figure 2b), further underlining the more 
substantial impact of LIG1 expression than cell cycle status for the occurrence of 17p TALEN-induced telomere 
fusions. The minor, but consistent, 1.62-fold (P = 0.044, Figure 2b and Supplementary Figure 2a) reduction in 17p 
fusions in G2-arrested compared with unsynchronised LIG3-/-:LIG4-/- cells supports the hypothesis that LIG1 ligates 
TALEN-damaged sister chromatids juxtaposed following replication, so that fusion frequency is enhanced as a 
function of repeated passage of unsynchronised cells through G2 phase.  
Whereas the 17p TALEN induces a single subtelomeric DSB initiating predominantly intra-chromosomal sister 
chromatid telomere fusions, the 21q TALEN induces DSBs in at least 19 distinct subtelomeres, so that the resulting 
telomere fusions can arise as a consequence of either inter- or intra-chromosomal recombinations. Variations in 21q 
TALEN-induced telomere fusion frequencies between LIG1-expressing and -depleted cells were notably more 
equivocal than those involving the 17p telomere (Figure 2a, 2d). A 2.76-fold reduction (P = 0.0444) in 21q fusions was 
measured for 4-OHT-treated LIG1-/flox:CreERt2 cells expressing only LIG3 and LIG4 compared with G2-arrested LIG3-/-
:LIG4-/- cells expressing only LIG1. Although not statistically-significant, a congruent 3.72-fold (P = 0.0625) 
depreciation in 21q fusion frequency was determined for LIG1-/flox:CreERt2 cells following LIG1 deletion. These 
observations are compatible with a suppression of sister chromatid fusions, but not inter-chromosomal fusions 
involving the related 16p and 21q telomeres in the absence of LIG1 (Figure 2d and lower 21q probe panels of Figure 
2a and Supplementary Figure 2a). Thus, the more overt and persistent differential in 21q fusion frequency between 
the LIG3-/-:LIG4-/- and LIG1-depleted LIG1-/flox:CreERt2 cells than between haploinsufficient MeOH or 4-OHT-treated LIG1-
/flox:CreERt2 logically correlates with LIG1 allelic dosage and expression. However, the considerable homology shared 
amongst 16p/21q telomere family members obviates formal verification of the particular requirement for LIG1 in sister 
chromatid fusions since inter- and intra-chromosomal fusions cannot be readily distinguished for independent 
quantification. In stark contrast, WT cells replete for all ligases sustained a robust 17p and 21q TALEN-induced fusion 
response under conditions of both asynchrony (Supplementary Figure 2e) and G2-arrest following treatment with 4-
OHT or carrier control (Figure 2e). Ergo, NHEJ-mediated repair per se, comprising a diversity of inter- and intra-
chromosomal recombinations, is not cell cycle-restricted.  
To cross-validate these observations, we employed a LIG1-specific chemical inhibitor, L82 (23,46) (provided by Dr 
Alan Tomkinson, University of New Mexico, USA) to examine whether this would correspondingly prohibit sister 
chromatid telomere fusions. Treatment of WT and LIG3-/-:LIG4-/- cells with even moderate levels (5 µM compared with 
in vitro IC50 of 12 + 2 µM (23)) of this inhibitor resulted in augmented proportions of G2/M phase cells (defined by 
pHH3 expression) compared with untreated cells assayed at 12 and 24 hr time points (Supplementary Figure 2f(i); 
central panels). Transient expansion of the G2/M fraction in response to L82 was described previously in accordance 
with the S-phase block caused by LIG1 functional inhibition (Supplementary Figure 2f(i)). Appropriately, L82 had the 
inverse effect in HCT116 TP53-/- cells (1.41-fold reduction; Supplementary Figure 2f(i) lower tier and summary plots) 
that have compromised cell cycle checkpoint regulation (58) and hence failed to arrest in response to replication 
errors elicited by LIG1 inhibition. Whilst the increase in mitotic fractions was comparable for WT and LIG3-/-:LIG4-/- 
cells after 12 hr, the proliferative capacity of the LIG3-/-:LIG4-/- cells was notably subdued by L82 over 24 hr, resulting 
in a reduced fold change compared with the WT (Supplementary Figure 2f(i), lower panel and summary charts). 
Hence, L82 has a more potent impact on cells expressing only LIG1. This is further illustrated in Supplementary 
Figure 2f(ii) that presents the 1.74-fold lesser increase in population growth for L82- compared with DMSO carrier 
control-treated LIG3-/-:LIG4-/- cells over 48 hr (upper panel). This suppressed proliferation corresponded with a 1.67-
fold contraction of S-phase cell fractions (central and lower panels), as expected from the inhibition of LIG1 catalytic 
activity that is required for DNA replication. 
Vitally, LIG3-/-:LIG4-/- cells treated with cytostatic (50 µM) doses of L82 suffered a pronounced decrease in 17p 
TALEN-induced sister chromatid fusions amplified from both unsynchronised and G2-arrested cells (Supplementary 
Figure 2g(i), upper panels, 2g(ii), left panel) that paralleled the loss of 17p sister chromatid fusions associated with 
LIG1 deletion in LIG1-/flox:CreERt2 cells (Figure 2a and Supplementary Figure 2a). The suppression was, again, more 
marked under conditions of G2-arrest (2.35-fold reduction, P = 0.014), emphasising the considerable contribution of 
LIG1 to DNA repair in this phase. The deficit in 17p fusions was not accompanied by a proportionate reduction in 21q 
TALEN-induced fusions (Supplementary Figure 2g(i), lower panels, 2g(ii), right panel), in keeping with the lesser 
impact of LIG1 deletion for these fusions that conceivably represent predominantly inter-chromosomal events. These 
results underscore the key and non-redundant contribution of LIG1 to sister chromatid but not uniquely to inter-
chromosomal telomere fusions. 
LIG1-depleted cells display an intact DNA damage response 
The conspicuous cell cycle-independent decreases in telomere fusion frequencies detected in LIG1-depleted HCT116 
could result from attenuated DNA damage responses (DDR) to TALEN-induced DSB. To determine whether the 
source of the differential fusion frequency related to DNA damage sensing, rather than DNA repair activity, we 
measured phosphorylation of histone H2AX (gH2AX) as a biomarker of DSB (Figure 3a). Untransfected proliferating 
HCT116 cells routinely exhibit a baseline gH2AX activation in circa 1-2% of the total population (Figure 3a, WT 
Untreated histogram), however, G2-arrest and transfection elevated this baseline > 10-fold to levels exceeding those 
measured in response to hydroxyurea-induced replication stress (8% gH2AX-staining cells; Figure 3a). Notably, 4-
OHT-mediated LIG1 deletion resulted in increased, rather than diminished populations of gH2AX-expressing cells in 
samples transfected with control DNA plasmids (Figure 3a, right panel), evidencing the clear capacity of LIG1-/flox:CreERt2 
cells for DDR activation following abrogation of DNA replication. Transfection with 17p TLN did not further exacerbate 
the detected DDR, conceivably owing to more extensive cell death in these samples. Whilst the differences in mean 
proportions of MeOH versus 4-OHT-treated gH2AX-expressing LIG1-/flox:CreERt2 cells were not statistically significant, 
these data affirm that LIG1-depleted cells are competent to sense and respond to DNA damage, coordinate with the 
robust cell cycle arrest indicative of checkpoint activation (Figure 1e, Supplementary Figure 1d). Furthermore, we 
noted that arrest of LIG1-depleted cells in G1 or G2 cell cycle phases did not promote the onset of a senescent 
phenotype (as measured by expression of HMGA2 (56), DPP4 (55) (Supplementary Figure 1i(iv) and Supplementary 
Figure 3a) and IL6 (59) (undetected) that could confer resistance or impede responses to DSB (60) (61). 
Mitotic slippage is suppressed in ligase-deficient cells  
Prior to nucleofection, G2-arrested WT, LIG3-/-:LIG4-/- and LIG1-/flox:CreERt2 samples displayed significantly divergent 
proportions of cells with defined DNA content (Figure 3b(i)). Although all samples were unambiguously enriched for 
populations with 4N (replicated) DNA content, proportions with this ploidy were significantly elevated in LIG1-/flox:CreERt2 
subsequently treated with or without 4-OHT (Figure 3b(i); P = 0.0176, 3b(ii), 3b(iii); P < 0.05). In contrast, the 
proportions of LIG1-/flox:CreERt2 cells with > 8N DNA content (representing polyploidy) were significantly lower than for 
WT and LIG3-/-:LIG4-/- cells (Figure 3b(i); P = 0.0289, 3b(ii), 3b(iii); P < 0.05). LIG1 deletion resulted in moderate 
reductions in both SubG1 apoptotic cells (Figure 3b(ii); 2.57-fold, P = 0.0003) and > 8N fractions (1.49-fold, P = 
0.0114), suggesting a potent G2-arrest. The lower > 8N fraction in LIG1-depleted cells than WT (2.76-fold P = 0.0286) 
LIG3-/-:LIG4-/- (1.71-fold P = 0.0119) and LIG1-/flox:CreERt2 MeOH-treated (1.49-fold P = 0.0114) cells (Figure 3b(ii) and 
3b(iii)) indicates a suppression of mitotic slippage and endoreplication towards a tetraploid state that could be 
expected to provide additional target substrate for TALEN cleavage activity.  
Post-nucleofection, the discrepancies between proportions of 4N and > 8N (8N+) DNA content populations in WT, 
LIG3-/-:LIG4-/- and LIG1-/flox:CreERt2 cells were further exaggerated (Figure 3c(i)). LIG1 depletion from the LIG1-/flox:CreERt2 
cells, again, resulted in a significant reduction in SubG1 constituents (1.83-fold, P = 0.0449), accompanied by an 
inflation of the 4N (1.33-fold, P = 0.0149), rather than the > 8N populations (Figure 3c(ii)) and signifying a heightened 
G2-arrest following transfection. TALEN expression or activity had minimal impact on these ploidy distributions in 
LIG1-haploinsufficient or -deleted cells (Supplementary Figure 3b, P > 0.5). Substantial enlargements of the > 8N 
distributions were observed for all samples (Figure 3c(i)), but the amplification was most striking amongst WT 
samples, for which this component rose from ~16% to ~61% of the total post-nucleofection and was 3.36-fold greater 
(P = 0.0143) than the equivalent fraction of LIG1-depleted cells (Figure 3c(iii)). LIG3-/-:LIG4-/- cells also demonstrated a 
greater proportion of > 8N cells than the LIG1-/flox:CreERt2 cells post-nucleofection that was further distended to a 1.59-
fold difference (P = 0.002) with LIG1 deletion (Figure 3c(iii)). The incrementally skewed ploidy of WT, LIG3-/-:LIG4-/- 
and LIG1-/flox:CreERt2 cells echoes the frequencies of TALEN-induced telomere fusions detected in these samples, such 
that the WT cells exhibited the highest frequency of telomere fusion and largest proportions of 8N+ cells, whereas the 
LIG1-/flox:CreERt2 cells displayed the lowest frequency of fusions and 8N+ cells (compare Figures 2a, 2e and 
Supplementary Figures 2a, 2e). These observations implicate polyploidy as an indicator of, or potential underlying 
mechanism contributing to, A-NHEJ-mediated telomere fusion and genomic instability (62). Incidence may, therefore, 
be a product of proliferative index in combination with capacity for DNA repair following transfection, resulting in 
differential prevalence and tolerance of mitotic slippage. However, the modest 1.49-fold (P = 0.0114) pre-
nucleofection and 1.25-fold (P = 0.1808, NS) post-nucleofection reductions in > 8N proportions in LIG1-/flox:CreERt2 cells 
versus LIG1-depleted LIG1-/flox:CreERt2 cells do not equate with the profound suppression of 17p sister chromatid fusions 
determined (Figure 2a, upper panel). Thus, the relative functions of LIG1 in DNA replication and repair contribute 
independently and potentially cumulatively to the incidence of telomere fusions. 
LIG1-mediated sister chromatid fusions amplified from G2 cells display asymmetric error rates 
Our previous high-resolution characterisation of telomere fusions mapped from Illumina paired-end sequencing 
yielded valuable insights into the molecular features of specific DNA repair activity (21). To further examine the 
consequences of LIG1-mediated sister chromatid telomere fusion, we focussed on G2 cell cycle phase cells in which 
LIG1 DNA repair activity could be functionally uncoupled from its requisite role in DNA replication. We performed 
Illumina paired-end sequencing of pooled 17p-17p (single primer) telomere fusion amplicons derived from multiple 
transfections of G2-arrested LIG3-/-:LIG4-/- cells with 17p TALEN nucleases harvested after 24 hr. Discordant read-
pairs aligned in an orientation predicted to arise as a consequence of sister chromatid 17p fusion were identified and 
sequence-validated to define precise fusion junctions. This dataset was juxtaposed with the 48 hr subset extracted 
from our former pooled 48 and 120 hr Illumina sequencing datasets of 17p TALEN-induced sister chromatid fusions 
amplified from unsynchronised LIG3-/-:LIG4-/- cells (21) in novel analyses intended to spotlight LIG1-specific repair 
features (Figure 4). Since LIG4 is essential for inter-chromosomal and not intra-chromosomal fusions, we performed 
comparisons of the LIG3-/-:LIG4-/- datasets with only inter-chromosomal telomere fusions derived from a nuclear LIG3-/- 
HCT116 model of LIG4-dependent C-NHEJ described in the same study (21). 
As anticipated, telomere fusions were characterised by a stereotypical length asymmetry of contributing sister 
chromatids that resulted in bi-modal distributions of deletion distances from the TALEN-cleaved breakpoint (Figure 
4a). These deletion profiles were analogous (P = 0.143) amongst both LIG3-/-:LIG4-/- datasets (unsynchronised mean 
of 1.28 kb, G2-arrested mean of 1.3 kb) and only moderately divergent from the LIG3-/--derived fusions (mean of 1.0 
kb). There was a comparable parity of microhomology usage (Figure 4b) at fusion junctions of unsynchronised (mean 
of 2.87 bp) and G2-arrested (mean of 2.77 bp) LIG3-/-:LIG4-/- cells, suggesting a commonality of underlying processes, 
regardless of compromised cytokinesis and replication stalling in G2-arrested cells. Microhomology usage at LIG3-/- 
inter-chromosomal fusion junctions was prominently 2-fold lower than for the LIG3-/-:LIG4-/- cells (P = 0.0427), 
affirming a more error-prone mechanism of DSB DNA repair at subtelomeres prosecuted by LIG1 and consistent with 
former definitions of A-NHEJ (21,35,36). Small (<50 bp) sequence insertions were detected at fusion junctions 
resolved from both unsynchronised and G2-arrested LIG3-/-:LIG4-/- cells (Figure 4c, 4d, 4e) with corresponding (P = 
0.4928) distributions (unsynchronised mean of 2.21 bp, G2-arrested mean of 3.46 bp). Comparison with C-NHEJ-
mediated (LIG3-/-) inter-chromosomal fusions was not appropriate since these events incorporate diverse genomic 
insertions. Rare fusions with long (> 10 bp) stretches of microhomology or larger (> 15 bp) insertions at the fusion 
junctions were evident in both LIG3-/-:LIG4-/- samples at indistinguishable levels. Insertions were predominantly 
templated from adjacent sequence regions (Figure 4d-e), emblematic of DNA polymerase theta (POLQ) engagement 
(63,64). These results serve to reinforce the supposition that LIG1 is competent and sufficient to effect A-NHEJ at 
telomeres, resulting in fusion of asymmetric sister chromatids via notable microhomology usage and POLQ-mediated 
DNA synthesis. 
To further explore the asymmetry of fused sister chromatids, we compared the sequence of centromeric (centromere-
telomere orientation of single fusion amplicon sequenced 5′ - 3′; more extensively-deleted) and telomeric (telomere-
centromere orientation; minimally-deleted) constituents of each fusion amplicon read-pair (illustrated in Figure 4f). 
Rationally, we identified an elevated error rate per kilobase (kb) for all sequence read-pairs derived from G2-arrested 
compared with unsynchronised LIG3-/-:LIG4-/- cell samples (Figure 4g). Specifically, the centromeric (blue symbols) 
read-pair components sequenced from G2-arrested cells displayed an 8.55-fold higher error rate than centromeric 
read-pair components from unsynchronised cells (P < 0.0001) and a correspondent 4.32-fold (P = 0.0081) increase in 
errors within telomeric read-pair components was also identified. These observations may evince the particular activity 
of LIG1 localised at stalled replication forks within late-replicating subtelomeric heterochromatin that subsequently 
mature into telomere fusions under prolonged G2-arrest (Figure 4f). More intriguingly, the relative sequence fidelity of 
centromeric and telomeric fusion read-pair components also differed significantly within the G2-arrested LIG3-/-:LIG4-/- 
sample (Figure 4g). The rate of erroneous nucleotide incorporation into the shorter centromeric read-pair components 
(blue symbols) was double (P = 0.0331) that detected for the telomeric read-pairs (red symbols). This differential 
repair fidelity denotes an asymmetry of mutational load for the fused sister chromatids that complements the length 
asymmetry described in Figure 4a and portrayed in Figure 4f. Polarised length and mutational burden of contributing 
sister chromatids may reflect the intrinsic inequality of strand synthesis and LIG1-dependent Okazaki fragment ligation 
(Figure 4f). 
Ligase-depleted cells maintain residual capacity for inter-chromosomal telomere fusion 
Whereas LIG1-expressing LIG3-/-:LIG4-/- cells were replete for 17p sister chromatid and 16p/21q family inter-
chromosomal telomere fusions (Supplementary Figure 2a), the sole deletion of LIG1 had a palpably more prohibitive 
impact on sister chromatid fusions than on inter-chromosomal fusions (Figure 2a-d, Supplementary Figure 2a). These 
observations raise the possibility of ligase-independent processes, as well as complementary involvement of LIG1 and 
LIG4, in these long-range interactions in G2-arrested cells. To discern ligase-independence or redundancy, we 
generated and employed additional HCT116 genetic models. Two haploinsufficient LIG1 conditional deletion clones 
(C15-5 and C15-9) were created from the LIG3-/-:LIG4-/- HCT116 cell line (Supplementary Figure 4a, 4b, 4c), so that 4-
OHT could, again, activate Cre-mediated excision of the single remaining LIG1 allele to rapidly render cells devoid of 
all nuclear DNA ligases under asynchronous (Supplementary Figure 4c) or G2 cell cycle conditions (Supplementary 
Figure 4d). Accordingly, LIG1 deletion was associated with a prominent 1.5-fold decrease in LIG1 protein 
(Supplementary Figure 1c) corresponding to a 1.5-fold decrement (P = 0.0096) in LIG1 mRNA measured after 24 hr 
(Supplementary Figure 4c(iii)). Consistent with our observations with the LIG1-/flox:CreERt2 cells (Supplementary Figure 
1g, 1h), 4-OHT-mediated LIG1 depletion reproducibly induced considerable alterations in the morphology of the LIG3-/-
:LIG4-/-:LIG1-/flox:CreERt2 clones (Supplementary Figure 4d(ii)), further evidenced by the significant ~ 1.1-fold increases in 
mean cell diameter (Supplementary Figure 4d(iii), unsynchronised C15-5; P = 0.0019, C15-9; P = 0.0047, G2-arrested 
C15-5; P = 0.0172, C15-9; P =NS). These data reinforce our suppositions that LIG1 function has diverse effects on 
subcellular organisation that may be direct or indirect via DNA damage signalling and cell cycle checkpoint activation. 
Importantly, and comparable with the LIG3- and LIG4-proficient LIG1-depleted cells, 17p TALEN-induced sister 
chromatid fusions were abolished by 4-OHT treatment of the LIG3-/-:LIG4-/-:LIG1-/flox:CreERt2 cells (Clones C15-5 and 
C15-9), but not parental clone lacking the CreERt2 transgene (C15) (Figure 5a). This loss of 17p sister chromatid 
fusions was coincident with cell cycle arrest and expanded proportions of > 4N DNA content cells following 4-OHT-
induced LIG1 deletion (Figure 5a, DNA content histograms displayed in lower panel). In contrast, 21q TALEN-induced 
fusions persisted in LIG1-depleted LIG3-/-:LIG4-/-:LIG1-/flox:CreERt2 cells even when standardising and restricting cell 
cycle progression using nocodazole (Figure 5b). Both LIG3-/-:LIG4-/-:LIG1-/flox:CreERt2 clones showed reduced (5-fold; 
C15-5, 2-fold; C15-9) 21q fusion frequency compared with the parental line, C15 (Figure 5c), but LIG1 depletion in 
response to 4-OHT treatment did not further dramatically curtail these events. Transfection efficiencies of LIG3-/-:LIG4-
/-:LIG1-/flox:CreERt2 clones and parental samples were approximately equivalent and did not account for variations in 
fusion frequencies (Figure 5b, recorded below panels). Thus, a subset of telomere fusions activated by a subtelomeric 
DSB appear to arise from ligase-independent DNA repair mechanisms operating in post-replicative G2-arrested cells. 
Interestingly, the 21q telomere fusions residually occurring in ligase-deficient cells demonstrated a contracted 
molecular weight distribution focussed within a 2-4 kb range and a notable absence of larger 8-12 kb amplicons, 
indicating alternative processing explicitly utilised in this repair pathway. These 21q telomere fusions were intractable 
to comprehensive sequence characterisation, suggesting challenging structure or repetitive composition. Rare events 
that could be resolved revealed recombinations involving subtelomeric fragmentation and inversion (Supplementary 
Figure 5), conceivably diagnostic of repair processes such as single-strand annealing (65). Since the 21q TALEN 
pairs cleave multiple subtelomeres, fusions may incorporate diverse genomic loci or employ uncut homologous 
template for recombination or synthesis-based repair (66). Novel approaches to characterise these challenging 
templates will be required to fully understand the range of DNA repair options that can be substituted to safeguard 
genome stability. 
Discussion 
We previously postulated a role for LIG1 in mediating intra-chromosomal telomere fusions in the context of impaired 
A- and C-NHEJ resulting from the genetic ablation of nuclear LIG3 and LIG4, respectively. Our current data, derived 
from a novel conditional targeting of human LIG1, not only supports this hypothesis, but also reveals an absolute and 
non-redundant requirement for LIG1 in the fusion of nuclease-targeted sister chromatid telomeres post-replication. 
LIG1 depletion impairs replication in a rapidly-dividing human cancer cell line 
Investigations into the particular contributions of LIG1 to DNA replication and repair have historically returned diverse 
and often contradictory results concerning the cellular requirements for and functions of this ligase. Targeted deletion 
of LIG1 in mouse embryos was found to be lethal (67) and antisense oligonucleotides targeting LIG1 transcripts in 
human tumours have achieved effective suppression of tumour growth (10). Conversely, other mammalian models 
(predominantly mouse) demonstrate a non-essential role for LIG1 (24-28,33,68,69) and propound functional 
substitution with LIG3. Discrepancies may relate to both the mechanisms and degrees of LIG1 elimination, as well as 
the experimental time-scale and specific processes investigated. Inherent differences between model organisms may 
also provide a heterogeneous context within which to examine LIG1 function, given the varied degrees of conservation 
of DNA ligases amongst eukaryotes (1). For these reasons, we have examined the unequivocal contribution of LIG1 to 
a specific DNA repair mechanism that operates at dysfunctional telomeres in a human cancer cell line. Our unique 
model allows for comparison of telomere recombination profiles amongst related cell lines with distinct repair pathway 
component deletions, thus permitting stringent resolution of key protagonists (21). The precise temporal control over 
LIG1 depletion afforded by our conditional recombination approach has permitted evaluation of the acute and direct 
impact of this ligase in specific repair processes at defined cell cycle stages.  
During the development of our novel LIG1-deficient HCT116 cell line, we found homozygous null cells could never be 
propagated. This is consistent with an indispensable role of LIG1 in DNA replication, further underscored by the robust 
cell cycle arrest achieved within 24 hr of the induced recombination of the remaining intact LIG1 allele in LIG1-
/flox:CreERt2 cells. In addition, we noted the restricted supernumerary ploidy expansions of LIG1-depleted cells in 
response to DNA damage and replication stress. Notably, the transcription of LIG3 and LIG4 was moderately 
increased by the depletion of LIG1 in unsynchronised and G1 phase cells and largely unaffected in G2 phase cells, so 
these results corroborate an incapacity of LIG3 to compensate for the loss of LIG1 in supporting DNA replication. 
Hence, although the catalytic capabilities of LIG1 and LIG3 may be analogous (1), temporal, spatial or kinetic 
constraints (31,32) seemingly prevent functional complementation in rapidly-propagating cells. The translational 
corollary of this is that LIG1 may be a valuable target for cancer therapeutics since proliferating rather than normal 
healthy somatic cells would be more severely afflicted.  
Our model also emphasises the capacity of critical cellular processes to be maintained by minimal levels of key 
components. We determined no limitations in population growth rates or viability of heterozygous LIG1 cells over short 
experimental time periods. In keeping with the survival of a patient with compound null and hypomorphic mutations in 
LIG1 into her late teens (11,12) and the successful propagation of 46BR fibroblast lines derived from this same patient 
(14,15), attenuated LIG1 expression or activity does not abrogate cell viability. Furthermore, nuclease-induced 
telomere fusions were unequivocally amplified from LIG1-/flox:CreERt2 and LIG3-/-:LIG4-/-:LIG1:-/flox:CreERt2 cells harbouring 
only a single intact LIG1 allele. Hence, although thresholds may determine repair outcomes and cell fate in certain 
circumstances (70), cellular dependence on LIG1 appears to be elemental rather than graduated, so that even 
diminished functional levels can effectively sustain DNA replication and repair. 
LIG1 depletion alters morphology and adhesion of cancer cells 
The genetic ablation of LIG1 exons encoding the catalytic and DNA binding domains rapidly instigated a remarkable 
transformation in cell morphology. We observed an increase in mean cell size that surpassed the customary 
enlargement associated with mitotic progression (71) and was unparalleled in the WT and LIG3-/-:LIG4-/- lines. This 
cellular expansion may reflect karyotypic and metabolic changes resulting from the impaired DNA replication and 
repair activity specifically in the LIG1-depleted cells. Increased cell volume may also be a factor of both micronuclei 
formation (29) and mitochondrial compensatory biogenesis in response to the replication stress caused by defective 
lagging strand synthesis (72,73) in LIG1-deficient cells. LIG1 insufficiency has also been associated with cellular 
'adaptation' that describes ongoing cell division despite unresolved DNA lesions (54) (74). Although we also 
determined substantial activation of DNA damage markers following LIG1 deletion, our model employing nocodazole-
induced G2-arrest and observations of reduced proportions of LIG1-depleted cells with > 8N DNA content precludes 
explanations of mitotic slippage and polyploidy as agents of cellular expansion. 
Instead, our data support the premise that LIG1 may impact genome integrity via modulation of cytoskeletal 
interactions and dynamics following the onset of quiescence (57). We detected considerable changes in adhesion 
properties of LIG1-depleted HCT116 that are in agreement with previous reports of differential cadherin expression in 
46BR.1G1 LIG1-deficient fibroblasts (54,75). The dramatic transformation of rounded self-aggregating LIG1-/flox:CreERt2 
cells into flattened monolayers following 4-OHT treatment is indicative of substantial cytoskeletal reorganisation with 
LIG1 depletion. Where previously cell cycle progression has been considered to be regulated by altered cell-cell and 
cell-matrix interactions (76), the collective descriptions of modified adhesion in LIG1-deficient cells raises the intriguing 
possibility that DNA replication and repair may coordinate the cytoskeletal rearrangements that precipitate mitotic 
rounding and cytokinesis (71,77). Changes in cellular adhesion impact tumour-stroma interactions, conferring 
resistance to DNA damaging therapeutics and predisposing to metastatic transformations (78-81). Thus, LIG1 
provides scope to understand the fundamental and pervasive connections between DNA replication, repair, 
cytoskeletal organisation and intracellular signalling that are transformative in cancer. 
LIG1 is necessary and sufficient for sister chromatid telomere fusion in the G2 cell cycle phase 
We previously proposed a role for LIG1 in mediating telomere fusions in the absence of LIG3 and LIG4 (21). In the 
current study, we directly compared the incidence of TALEN-induced telomere fusions in LIG1-depleted HCT116 cells 
with those derived from cells expressing only LIG1 (LIG3-/-:LIG4-/-) and cells depleted of all three DNA ligases. We 
demonstrated the persistent and compelling occurrence of sister chromatid (17p) and inter-chromosomal (21q) 
telomere fusions in LIG3-/-:LIG4-/- cells under conditions of asynchrony and G2-arrest, establishing that LIG1, alone, is 
sufficient to support telomere recombinations comparable to ligase-replete WT cells. High-resolution sequencing of 
LIG1-mediated telomere fusions derived from LIG3-/-:LIG4-/- cells revealed features characteristic of the A-NHEJ repair 
implicated in fusions resulting from both telomere attrition (36) and nuclease-targeting (21), including microhomology 
usage and deletion at junctions. Notably, we identified fusions that contained insertions templated from adjacent sister 
chromatid sequence reminiscent of the templated insertions introduced during DNA POLQ-mediated end-joining 
(63,82) (83).  
In flagrant opposition, the singular deletion of LIG1 from LIG1-/flox:CreERt2 cells resulted in the complete abrogation of 
sister chromatid telomere fusions in G2-arrested cells that retained expression of LIG3 and LIG4. Whilst we were 
unable to formally prove that the 21q fusions sustained in the absence of LIG1 comprised inter-chromosomal rather 
than sister-chromatid fusions, the ~3-fold decreases in the frequency of these events amplified from LIG1-depleted 
cells approximated the ~13-fold reductions determined specifically for 17p sister chromatid fusions, suggesting the 
loss of a related subset of events. These results reveal a non-redundant requirement for LIG1 in distinct post-
replicative DNA repair processes, as well as in replication per se. As for DNA replication, LIG3 and LIG4 do not 
provide functional compensation in sister chromatid telomere fusion, thus conflicting with the premise that ligases are 
operatively interchangeable (24,68). Importantly, though, our data are compatible with the failure of LIG3 to rescue the 
specific telomere instability induced by the shRNA-targeted depletion of LIG1 reported by Le Chalony et al. (26), as 
well as the unique capacity we described for LIG3 in facilitating escape from a telomere-driven crisis (34). Crucially, 
the remarkable requirement for LIG1 to mediate sister chromatid fusion in cells fully proficient for C-NHEJ negates the 
supposition that this constitutes a mere auxiliary repair pathway.  
Post-replicative repair is critical both in quiescent cells (84) and in proliferating cells for the resolution of lesions that 
elicit replication fork stalling, compromising the completion of late-replicating loci including telomeres and other 
heterochromatin regions (85,86). Telomeres present a unique susceptibility to DNA damage following replication 
stress and fork collapse since their distal chromosomal locations precludes rescue by obverse fork movement. 
Structural complexities arising from G quadruplex and R-loop formation generate further obstacles to the replication 
machinery at telomeres, contributing to exacerbated replication stress and fork destabilisation through the formation of 
RNA-DNA hybrids that expedite genomic instability (87) (88). Hence, post-replicative telomere DNA repair must be 
regulated to restrict gross telomere deletion and recombination that could be lethal or transformative (89,90).   
Mechanistically, LIG1 is optimally-positioned to coordinate DNA repair at the replication fork in S/G2 cell cycle phases 
(7) when it is juxtaposed with nascent lagging strand DNA (91). This uniquely capacitates LIG1 for the repair of 
TALEN-induced DSB in late-replicating subtelomeric sequence, elucidating the absolute requirement we uncovered 
for this ligase for sister chromatid telomere fusion. Our proposition that LIG1 profoundly influences cytoskeletal 
interactions may account, in part, for the categorical loss of these fusions when LIG1 is deleted. Cytoskeletal 
dynamics are increasingly being recognised as integral to the transmission of the DDR (92) and translation into DNA 
repair pathway selection (93,94). Conceptually, the absence of LIG1 could affect subnuclear localisation of damaged 
subtelomeres that, in the context of sustained replication stress and cell cycle arrest, could license more effective 
activation of homologous or heterologous recombination (66,95) in preference to NHEJ-mediated telomere fusion. 
Cytoskeletal dynamics are also of fundamental importance to chromosome motility and scheduled segregation at 
mitosis (77), suggesting an additional level of interconnection between LIG1 function and ploidy or aneuploidy. We 
documented a significant suppression of ploidy accretion in LIG1-depleted cells that could be expected to 
concomitantly reduce the opportunity for telomere fusion and constrain the consequent precipitous genomic instability 
(62,96) (97). Recent elucidation of the mechanisms integrating DNA replication and sister chromatid cohesion (98) 
present additional possible explanations for the dearth of sister chromatid fusions in LIG1-deficient cells. As with other 
replication factors (99), LIG1 may be integral to coordinated replication and sister chromatid cohesion, such that the 
cohesion fatigue likely experienced by cells held in prolonged G2-arrest is heightened in its absence. Weaker or more 
transient cohesion could hence reduce interaction and, as a corollary, fusion incidence between damaged sister 
chromatid telomeres subjected to NHEJ. By association, impaired cohesion also facilitates more extensive DNA 
resection that assists homology-directed repair rather than NHEJ (98,100). 
Differential requirement for LIG1 at inter-chromosomal telomere fusions 
Our data reveal a divergent dependence of sister and inter-chromosomal telomere fusions on LIG1 activity that 
highlights the co-existence of distinct and conceivably competitive DNA repair processes in post-replicative cells. 
Whereas 17p sister chromatid telomere fusions were undetectable in the absence of LIG1, 21q inter-chromosomal 
fusions between related homologous family members were less severely diminished. The LIG1 non-competitive 
inhibitor, L82 (23,46), also had limited effect on these inter-chromosomal fusions, although highly-effective in 
suppressing LIG1-dependent sister chromatid fusions. Thus, inter-chromosomal telomere fusions are predominantly 
mediated by repair that operates synonymously with or independently of LIG1 catalytic activity. Since the 21q TALEN 
cleaves multiple homologous chromosome ends, the disparity in LIG1 involvement may arise as a factor of lesion 
prevalence, as well as the engagement of explicit DNA repair. Feasibly, the augmented propensity for aneuploidy and 
mis-segregation intrinsic to chromosomes targeted by the 21q TALEN compared with the 17p TALEN may contribute 
to the activation of more global genomic instability, as well as a broader range of DNA repair mechanisms (101). 
Notably, interactions between damaged subtelomeres of different chromosomes will not share the same susceptibility 
to replication factor engagement as those consequent of sister chromatid cohesion (99), elucidating the differential 
impact of LIG1-depletion for these inter-chromosomal fusions. The contribution of LIG4 to such long-range inter-
chromosomal recombinations has been established by our group and others, however, our current study reveals this 
function may be transposable by LIG1 and possible supplementary mechanisms in G2-arrested cells.    
Intriguingly, an unanticipated residual capacity for inter-chromosomal telomere fusions was uncovered using cells 
deficient in all three DNA ligases. Whilst we cannot absolutely exclude the prospect that these fusions were 
prosecuted by residual or N-terminal truncated LIG1 proteins in the 4-OHT-treated LIG3-/-:LIG4-/-:LIG1-/flox:CreERt2 cells, 
we detected no symptomatic recovery from the potent cell cycle arrest induced by LIG1 deletion. Similarly, the 
potential for mitochondrial LIG3 to rescue the defective NHEJ in nuclear ligase-depleted cells endures, but has not 
formerly proven significant even in cells facing the severe selection pressures of a telomere-driven crisis (34). 
Importantly, the molecular weight distributions of telomere fusions amplified from LIG1-deleted LIG3-/-:LIG4-/-:LIG1-
/flox:CreERt2 cells were patently distinct from those amplified from LIG1-expressing (A-NHEJ-competent) cells. This 
diversification may implicate alternative ligase-independent repair mechanisms, including heterologous recombination 
(66), break-induced replication (102) or single-strand annealing. Further specialised investigation will be required to 
formally substantiate the ligase-independence and particular characteristics of these events, however. 
 
LIG1-mediated sister chromatid telomeric fusions display asymmetric processing 
We determined recurrent asymmetry of deletion from the subtelomeric nuclease cleavage site of paired chromatids 
comprising each sister chromatid telomere fusion amplified from both unsynchronised and G2-arrested LIG3-/-:LIG4-/- 
cells. The close correspondence with preceding datasets derived from diverse DNA repair deficient models (21) 
intimates a common and fundamental involvement of LIG1 in these particular recombinations. Integration of the 
biochemical pathways in which LIG1 is involved provides a rationale for the length asymmetry of fused chromatids 
(illustrated in 4f). Replication fork stalling in late-replicating subtelomeric sequence has the potential to result in the 
incomplete replication or truncation of one chromatid (103). LIG1 complexed with PCNA and unligated Okazaki 
fragments may nucleate fusion of leading and lagging strand DNA, facilitated by POLQ helicase activity (82,104) and 
stabilised by POLQ-mediated DNA synthesis (63,105). The templated insertions we observed at sister chromatid 
fusion junctions could equally arise as a consequence of the incorporation of ligation intermediates released by strand 
displacement DNA synthesis (31). The 17p sister chromatid telomere fusions we sequence-verified were 
predominantly composed of one chromatid truncated to the approximate length of an Okazaki fragment (<500 bp) and 
the other minimally-deleted from the TALEN cleavage site, compatible with a hypothesis of fusion as a recourse from 
or by-product of replication fork dysfunction. However, it remains plausible that the length asymmetry measured arises 
purely from disproportionate strand resection (106), generating substrates of discordant length for NHEJ.  
Superimposed upon the length asymmetry, we observed a remarkable discrepancy in mutational load for the paired 
constituents of sister chromatid fusions amplified from LIG3-/-:LIG4-/- G2-arrested cells. The significantly higher rate of 
erroneous nucleotide insertion we detected for the shorter 'centromeric' than the longer 'telomeric' components of 
these fusion pairs necessarily relates to inherent differences in the synthesis or processing of these chromatids that 
subsequently fuse within the same cell. We have postulated a correlation of nucleotide error rate with the distinct DNA 
polymerases responsible for synthesising leading versus lagging DNA strands (21,107,108). As an extension of this, 
an asymmetry of mismatch repair focused at Okazaki fragments of the lagging strand has recently been reported 
(109) that could underpin the discrepant mutation frequency at fused sister chromatids comprising paired long 
‘telomeric’ leading strand and short ‘centromeric’ lagging strand DNA. The apparent bias uncovered by the resolution 
specifically of G2 phase LIG1-mediated fusions may reflect a compounding decline in the repair of nucleotide damage 
incurred in exposed single-strand DNA (110) resulting from extensive resection or replication fork collapse in arrested 
cells. LIG1 is also a key component of the base excision repair that performs critical post-replicative processing of 
telomeric lesions to license faithful chromosome segregation at mitosis (111,112). Competing requirements for LIG1 
engagement in the context of DNA damage combined with replication stress may contribute to the exacerbated and 
polarised mutation distinguished for sister chromatid fusions derived from G2-arrested cells.  
 
Concluding remarks 
We have demonstrated a unique, cell cycle-independent and non-redundant role for LIG1 in sister chromatid telomere 
fusions, thus securely establishing LIG1 as not only an essential engineer of mitosis, but also as a critical post-
replicative repair enzyme. Central to both DNA replication and repair, LIG1 is uniquely-competent to orchestrate a 
coordinated response to lesions in late-replicating DNA, including at sites of replication fork collapse and telomeric 
sequences. As such, LIG1 may constitute a final opportunity to resolve persistent damage ahead of the mitotic 
progression that would expedite global and catastrophic genomic instability. We therefore propose LIG1 as an 
attractive therapeutic target for both oncology, where accelerated proliferation jeopardises consonant DNA synthesis 
and repair, as well as pathological contexts where the quality of post-replicative repair may critically influence disease 
progression. Importantly, our data provide further clarification for the separation of function of DNA ligases within 
mammalian cells that will be invaluable for devised therapeutic interventions. 
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Figure Legends 
Figure 1  
LIG1 deletion results in cell cycle arrest and morphological changes. (a) Resolution of LIG1 allelic recombination 
in 4-OHT and nocodazole-treated (G2-arrested) L1-/fx:Cre cells by agarose gel electrophoresis of genomic PCR 
products. Deleted/’floxed’ (D/Fx) allelic ratios (x10-2) are indicated above the sample lanes. No amplification from a WT 
HCT116 control (G+) or water blank (H-) was detected. (b) Quantification of the reduction in mean relative LIG1 
mRNA expression (Ex22_F and Ex23_R primers) in L1-/fx:Cre cells following 24 hr treatment with 4-OHT from 4 replica 
experiments with 95% confidence intervals. Statistical significance was evaluated using a paired one-tailed T-test. (c) 
The specific down-regulation of LIG1 mRNA expression (Ex22_F and Ex23_R primers) by 4-OHT treatment over 24 hr 
in unsynchronised or cell cycle G2- or G1-arrested L1-/fx:Cre cells from 3 replica experiments is depicted as a bar chart 
of mean fold change in expression with 95% confidence intervals. The dotted line illustrates a fold change of 1.0 (no 
change). (d) Comparison of WT, L3-/-:L4-/- and L1-/fx:Cre mean fold changes in 48 hr post-thaw cell counts with 95% 
confidence intervals from at least 4 independent experiments assessed by Kruskal-Wallis one-way ANOVA. (e) 24 hr 
treatment of treatment of L1-/fx:Cre cells with 4-OHT causes cell cycle arrest and loss of mitotic G2/M phase phospho-
histone H3 (pHH3)-expressing populations determined by flow cytometry. Mean data from 5 independent experiments 
with 95% confidence intervals displayed and assessed by paired sample one-tailed T-test. (f) Mean proportions of 
LIG1-/flox:CreERt2 cells with diploid (2N) and tetraploid (4N) DNA content from 4 independent experiments are plotted with 
95% confidence intervals and paired one-tailed T-tests between 2N and 4N DNA content fractions. (g) Changes in 
mean cell diameter induced by 24 hr MeOH (black shapes) or 4-OHT (white shapes) treatment of nocodazole G2-
arrested WT, L3-/-:L4-/- and L1-/fx:Cre cells from 3-9 independent experiments are shown as mean values with 95% 
confidence intervals. Unsynchronised untreated samples are displayed as hatched shapes. Unpaired one-tailed T-
tests between appropriate samples were performed. (h) Illustration of TALEN-induced (TLN) subtelomeric DSB 
resulting NHEJ-mediated fusion of replicated and cohered sister chromatids in G2 phase of the cell cycle. A single 
orientation primer (P) can be used to amplify these head-head sister chromatid fusions for Southern hybridisation or 
sequence analyses. 
Figure 2 
LIG1 is required for 17p sister chromatid telomere fusions. (a) Fusion amplicons derived from 17p or 21q TALEN 
(TLN) or control (0 DNA) -transfected unsynchronised or G2-arrested L1-/fx:Cre were visualised by Southern 
hybridisation using probes specific for the 17p (upper panels) or 21q subtelomeric (lower panels) sequence. A 2.9 kb 
constitutive amplicon band of known sequence identity is also detected with the 21q probe, but excluded from all 
fusion amplicon analyses. (b) Summary of 17p telomere fusion frequency (fusions/ng DNA input x10-2) data from 7 
independent 17p TLN and control (C) transfection experiments in unsynchronised (U) and G2-arrested (G2) L3-/-:L4-/- 
and L1-/fx:Cre  cells displayed as mean values with 95% confidence intervals with one-tailed paired T-tests or Mann-
Whitney U-tests, as appropriate. (c) Box and whiskers representation of 17p telomere fusion frequency data presented 
in (b) as a pooled data comparison of all 17p TALEN-transfected L3-/-:L4-/- (grey) samples with all MeOH-treated L1-
/fx:Cre (black) samples and compared by two-tailed Mann-Whitney U-test. (d) Summary of 21q telomere fusion 
frequency (fusions/ng DNA input x10-2) data from 3 independent 21q TLN and control (C) transfection experiments in 
G2-arrested L3-/-:L4-/- and L1-/fx:Cre cells displayed as mean values with standard deviation and one-tailed paired T-tests 
or Mann-Whitney U-tests, as appropriate. (e) Southern hybridisation images of G2-arrested WT 17p (upper panel) and 
21q (lower panel) fusion amplicons generated as in (a). Untransfected (t0) and control (GFP) transfections are 
included for comparison with 17p and 21q TLN-transfected samples.  
Figure 3 
LIG1-depleted cells maintain an intact DNA damage response and suppressed mitotic slippage. (a) Flow 
cytometry detection of the phosphorylated (Ser139) histone variant H2AX (gH2AX; red overlays) as a surrogate 
marker for DSBs in G2-arrested and 4-OHT-treated L1-/fx:Cre cells transfected with 17p TLN or 0 DNA control over 24 
hr. The top left insert shows a histogram of gH2AX-expressing (8% population; blue overlay) unsynchronised and 
untreated L1-/fx:Cre cells exposed to 2 mM hydroxyurea (HU) for 1 hour at 37°C. The bottom left insert reveals the basal 
1.6% gH2AX-expressing asynchronous and untransfected WT HCT116 cells. The right-hand bar chart shows mean 
proportions (with SD) of gH2AX-expressing G2-arrested L1-/fx:Cre cells 24 hr post-nucleofection (2 replicas). The 
proportions of cells with defined DNA content in 3 independent experiments as assessed by DAPI DNA staining of 
fixed G2-arrested WT, L3-/-:LIG4-/- and L1-/fx:Cre cells (b) pre-nucleofection or (c) 24 hr post-nucleofection (pooled 17p 
TLN and 0 DNA transfections) with detection by image cytometry. (i) Data for each fraction of pre- and post-
nucleofection samples is plotted as the mean with standard deviation and assessed using one-way Kruskal-Wallis 
ANOVA of individual population fractions (significance set as alpha = 0.05) recorded against the colour key code. 
Differences relating specifically to the 4-OHT-mediated deletion of LIG1 from L1-/fx:Cre cells are shown in 3b(ii) and 
3c(ii). Significance was assessed by one-tailed paired T-tests of common fractions. The significant (Mann-Whitney U-
tests, 0.05; *, 0.005; **) variations in proportions of WT, L3-/-:L4-/- and L1-/fx:Cre cells treated with 4-OHT are displayed in 
3b(iii) and 3c(iii). 
Figure 4 
LIG1-mediated sister chromatid telomere fusions resolved by high-resolution fusion amplicon sequencing. 
Illumina paired-end sequencing of 17p telomere fusion amplicons derived from 17p TLN-transfected unsynchronised 
L3-/- and unsynchronised or G2-arrested L3-/-:L4-/- HCT116 was analysed for features of A-NHEJ-mediated repair. (a) 
The distance from the 17p TLN cleavage site to the fusion junction of each contributing chromatid within 17p intra-
chromosomal fusions (L3-/-:L4-/-) or inter-chromosomal fusions (L3-/-) is plotted as mean deletion in kb with 95% 
confidence intervals and one-way Kruskal-Wallis ANOVA between samples. (b) The number of nucleotides (bp) with 
shared identity (microhomology at fusion junction) amongst participating sister chromatids constituting each 17p intra-
chromosomal fusion (L3-/-:L4-/-) or across 17p inter-chromosomal (L3-/-) fusion junctions is presented with means and 
95% confidence intervals, one-way Kruskal-Wallis ANOVA and two-tailed Mann-Whitney U-tests. (c) The number of 
nucleotides (bp) inserted within 17p intra-chromosomal L3-/-:L4-/- sample fusion junctions (not applicable to L3-/- inter-
chromosomal fusions) is shown with means and 95% confidence intervals with a two-tailed Mann-Whitney U-test. (d) 
The frequencies of events described in a-c are illustrated as a stacked column chart with colour key for 
unsynchronised and G2-arrested L3-/-:L4-/- samples. (e) Examples of 17p intra-chromosomal sister chromatid fusions 
mapped by Illumina paired-end sequencing from G2-arrested 17p TLN-transfected L3-/-:L4-/- cells. The centromeric 
(centromere-telomere orientation) component of each read pair is shown in blue, the telomeric (telomere-centromere 
orientation) component in red. Arrows indicate the direction of sequence and Dbp signifies the distance from the 17p 
TLN cleavage site. Templated (duplication) insertion and microhomology sequences underlined. (f) The centromeric 
components of sister chromatid fusion read pair (blue) have shorter mean lengths and increased mean nucleotide 
error incorporation rates than the telomeric components (red), resulting in asymmetric fusion molecules. Differences in 
(i) the fidelity of polymerase activity in leading (POLD/E) and lagging (POLA/POLD) strand DNA synthesis, as well as 
(ii) replication stress and fork collapse exposing lagging strand Okazaki fragments and ligation intermediates and (iii) 
strand bias in resection and/or deletion may contribute to both manifestations of asymmetry. C and T indicate the 
direction to the chromatid centromere and telomere, respectively. (g) Nucleotide incorporation error rate was 
calculated for both the centromeric (blue) and the telomeric (red) components of each 17p sister chromatid fusion read 
pair sequenced from L3-/-:L4-/- cells and presented with means and 95% confidence intervals. One-way Kruskal-Wallis 
ANOVA and two- (unsynchronised) or one (G2-arrested) -tailed Mann-Whitney U-tests were employed. 
Figure 5 
Ligase-depleted cells retain inter-chromosomal fusion capacity. (a) Southern hybridisation detection of 17p 
fusions amplified from control (0 DNA) and 17p TLN-transfected unsynchronised and 4-OHT-treated L3-/-:L4-/-L1-/fx:Cre 
(clones C15-5 and C15-9) and parental clone C15 (L3-/-:L4-/-L1-fx) cells harvested after 48 hr. Corresponding DNA 
content for each sample at the point of transfection is displayed below as linear histograms with annotated ploidy 
peaks. (b) Southern hybridisation detection of 21q fusions induced by transfection of G2-arrested and 4-OHT-treated 
L3-/-:L4-/-L1-/fx:Cre and L3-/-:L4-/-L1-fx cells with 17p and 21q TLN over 48 hr. Transfection efficiency (%) of each sample 
at 24 hr post-nucleofection is indicated in below the lanes. (c) Bar chart summary of 17p (left side) and 21q (right side) 
fusion frequency data displayed in (a) and (b) for parental L3-/-:L4-/-L1-fx clone C15 and L3-/-:L4-/-L1-/fx:Cre clones C15-5 
and C15-9 in the presence of MeOH or 4-OHT. 
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Supplementary Figure 1 
Generation and validation of an HCT116 conditional LIG1 deletion cell line. (a) Upper panel shows the targeting 
strategy employed to generate HCT116 LIG1
-/flox:CreERt2
 cell line using Cre recombinase-mediated recombination (loxP 
recognition sites marked as filled arrowheads) to excise exon 23 of human LIG1. Lower panel depicts the ‘floxed’ and 
deleted LIG1 alleles within a 1 kb sequence window and presents the comparative sequence of relevant domains: 
exon 22 is represented by a red block, exon 23 in blue and sequences replaced by loxP Cre recognition sites 
highlighted in yellow. Diagnostic primer binding sites for validation of allelic deletion are indicated as purple arrows. 
GRCh38 Chr19 genomic positions delineating the start and end of the relevant sequence window are indicated below; 
the sequence is colour-coded to match the diagrammatic representations above. (b)(i) Representative gel image (3 
experiments) comparison of LIG1 and YWHAZ housekeeping gene expression by RT-PCR in unsynchronised (U) and 
G1 or G2 cell cycle-arrested LIG1
-/flox:CreERt2
 cells treated with 4-OHT (+) or carrier control (-). Control samples were 
prepared without reverse transcriptase (RT-). A genomic DNA control sample is labelled as G+ and the water blank 
lane as H-. Molecular weight ladders (kb and 100 bp) were used to identify LIG1 cDNA amplified using Ex22_F and 
Ex23_R primers at 221 bp and YWHAZ cDNA at 211 bp. Normalised gene expression values (tester/YWHAZ) are 
shown below the lanes. Confirmation of the cell cycle status of the same cells is presented in (ii). (iii) RT-PCR 
detection of transcribed LIG1 exons 5′ (exons 4-5 and exons 17-19) or 3′ (exons 22-23) of the exon targeted for Cre-
mediated recombination (exon 23). Cell cycle-arrested and unsynchronised samples cultured in the presence or 
absence of 4-OHT were processed as in (i). Data are presented as mean fold change in mRNA expression for 4-
OHT/MeOH carrier control-treated samples in two experiments normalised to YWHAZ housekeeping gene expression 
with standard deviation (SD). The red dashes mark 1.0-fold (no) change in gene expression. (c) Representative 
western blot analysis (2 experiments) demonstrating substantial reduction in LIG1 protein (anti-LIG1 C-terminus 
polyclonal, upper panel; anti-LIG1 10H5 monoclonal, bottom panel) expression in 4-OHT-treated LIG1
-/flox:CreERt2
 (L1
-
/fx:Cre
) and LIG3
-/-
:LIG4
-/-
LIG1
-/flox:CreERt2
 (L3
-/-
:L4
-/-
L1
-fx:Cre
) clones C15-5 and C15-9 (see Supplementary Figure 4) but not 
WT, LIG3
-/-
:LIG4
-/-
 (L3
-/-
:L4
-/-
) or parental C15 LIG3
-/-
:LIG4
-/-
LIG1
-/flox 
(L3
-/-
:L4
-/-
L1
-fx
) cells. LIG1 protein signal 
quantification (x10
6
) is indicated above the appropriate bands in red. The central panel shows actin protein loading 
signal control. The lower bar chart displays the mean fold change (with standard error) in aggregated LIG1 protein 
expression detected with the C-terminal polyclonal and 10H5 monoclonal antibodies normalised to actin and 
constitutive protein loading signal determined by immunoblotting and membrane staining in 4-OHT-treated compared 
with MeOH-treated samples. The red dashes mark 1.0-fold (no) change in protein expression.  Statistical significance 
was assessed by one-tailed paired T-tests. (d)(i) Cell cycle analysis of single nuclei suspensions prepared from MeOH 
or 4-OHT-treated WT and L1
-/fx:Cre
 cells performed by flow cytometry detection of phospho-histone H3 (pHH3)-
expressing fractions (blue overlay, positive fractions marked with red bar and indicated as percentages in red). (ii) 
DRAQ5
TM
 DNA staining of the same samples presented in (i). Diploid nuclei with 2N DNA content and tetraploid nuclei 
with 4N DNA content and the relative population proportions are annotated. (e) The specific impact of 4-OHT on the 
proliferation of L1
-/fx:Cre
 and not L3
-/-
:L4
-/-
L1
-fx
, WT or L3
-/-
:L4
-/- 
cells is demonstrated as a chart of fold change in cell 
number over 24 hr following treatment with 4-OHT or MeOH carrier. (f) Confirmation of G2-arrest induced by 50ng/ml 
nocodazole in L1
-/fx:Cre
 cells over 24 hr. Upper panels show representative linear DAPI DNA stain signal intensity 
histograms with diagnostic DNA content peaks labelled. The lower panel shows mean population fraction data from 2 
replica experiments plotted as a stacked bar chart with SD. Fold changes in cell cycle fractions with 4-OHT or 
nocodazole treatment are listed in the table below, with statistical significance between sample populations tested 
using unpaired one-tailed T-tests. (g) Prototypical images of unsynchronised or G2-arrested (h) WT, L3
-/-
:L4
-/-
 and L1
-
/fx:Cre
 cells treated with 4-OHT for 24 hr is shown. Complete field of view images with 20X magnification are displayed 
with a 250 M scale bar. (i) Two independent cultures of L1
-/fx:Cre
 cells were treated with MeOH or 4-OHT for 24 hr 
ahead of 7 days' long term culture in standard medium.  Prototypical images with 20X magnification and a 250 M 
scale bar are shown in (i), fold change in population parameters over 7 days (4-OHT-/MeOH-treated) is shown in (ii), 
genomic PCR confirmation of LIG1 allelic recombination is presented in (iii) with quantification of the deleted/'floxed' 
signal intensity (x10
-2
) indicated above the appropriate bands in red. RT-PCR analysis of ligase (LIG1 Ex22_F and 
Ex23_R primers) and senescence-associated genes normalised to YWHAZ housekeeping gene control is displayed 
as fold change of 4-OHT-/MeOH-treated cells in (iv).  
 
  
Supplementary Figure 2 
LIG1 plays a non-redundant role in sister chromatid telomere fusion. (a) Fusions induced by 17p and 21q TALEN 
(TLN) pairs in unsynchronised and G2-arrested L3
-/-
:L4
-/- 
cells (left panels) juxtaposed with data for the 4-OHT-treated 
L1
-/fx:Cre
 (right panels) formerly presented in Figure 2 (a). 17p telomere fusions (upper panel) and 21q telomere fusions 
(lower panel) were visualised with specific hybridisation probes. (b) 17p telomere sister chromatid telomere fusions 
amplified by single 17p primer fusion PCR from unsynchronised (upper) and G2-arrested (lower) 17p and 21q TLN-
transfected carrier and 4-OHT-treated LIG1
-/flox:CreERt2
 (L1
-/fx:Cre
) cells prepared as in (a) and detected using the 17p 
subtelomere probe. (c) Transfection efficiency of WT, L3
-/-
:L4
-/- 
and L1
-/fx:Cre
 G2-arrested cells measured as proportions 
of viable GFP-expressing cells at 24 hr post-nucleofection. Mean proportions calculated from 2-5 independent 
experiments are plotted with SD and statistical significance assessed by unpaired one-tailed T-tests with Welch's 
correction applied for the combined WT versus L1
-/fx:Cre
 tests. (d) Titration of DNA input of LIG1-depleted sample into 
17p single primer telomere fusion PCR. Input gradient illustrated with black triangle and ng DNA amounts listed above 
lanes. Abundant 17p fusions amplified using 100 ng/reaction HCT116 WT DNA are shown for comparison (centre). An 
independent replica of paired carrier and 4-OHT-treated L1
-/fx:Cre
 carrier using 100 ng DNA/fusion PCR was performed 
in parallel (right-hand lanes). (e) Southern hybridisation images of 17p (upper panel) and 21q (lower panel) TLN-
induced fusion amplicons derived from two replica (adjacent lanes) samples of unsynchronised WT HCT116 
generated as in (a). (f)(i) Confirmation of L82 LIG1 inhibitor functional activity in HCT116 WT, L3
-/-
:L4
-/-
 and TP53
-/-
 
cells. Cells were cultured under conditions of serum starvation (0.1% FCS) for 6 days before being recovered into 
20% FCS-containing medium supplemented with 5 M L82 or carrier control (untreated) for a further 12 or 24 hr, as 
indicated (t12, t24). WT  flow cytometry detection of cells were used to calibrate the phospho-histone H3 (pHH3)-
expressing G2/M phase mitotic fractions (percentages indicated in red) in experimental samples (central dot plots) 
compared with no antibody (no ab) and untreated controls. The lower panels show the overlaid proportions of pHH3-
expressing mitotic cells in 24 hr untreated (black) or L82-treated (red) samples. The L82-induced fold changes 
(L82/untreated) in pHH3-expressing mitotic fractions in t12 (left) and t24 (right) WT (white), L3
-/-
L4
-/-
 (grey) and TP53
-/-
 
(black) samples are expressed as bar charts below with fold-change values in red. (ii) Validation of L82-mediated 
inhibition of LIG1-dependent cell cycle progression in L3
-/-
:L4
-/-
 cells. L3
-/-
:L4
-/-
 cells were counted and plated 24 hr 
prior to being treated with 50 M L82 or DMSO carrier control for an additional 24 or 48 hr in two experiments. Cells 
harvested at 24 and 48 hr were counted and processed for cell cycle analysis. The upper chart shows population 
growth and the central panel shows altered cell cycle distributions in response to the treatments. The lower panel 
specifically charts the mean change in S-phase fractions after 24 and 48 hr plotted with SD. 
 
(g) (i) Southern hybridisations of 17p (upper panel) and 21q (lower panel) telomere fusions amplified from 50 M L82-
treated L3
-/-
:L4
-/-
 cells 48 hr post-nucleofection with 17p and 21q TLN or 0 DNA controls are shown. (ii) 17p (left) and 
21q (right) fusion frequencies calculated from 3 independent experiments are summarised as means with 95% 
confidence intervals and differences tested using one-tailed paired T-tests.  
  
Supplementary Figure 3 
LIG1-depleted cells display an intact DNA damage response. (a) The expression of senescence-associated 
(DPP4 and HMGA2; 3 replicas) and TP53-activated (CDKN1A; 2 replicas) genes in unsynchronised and G2- or G1-
arrested L1
-/fx:Cre
 cells harvested after 24 hr was analysed by RT-PCR and displayed as mean fold change with SD of 
4-OHT-/MeOH-treated cells normalised to YWHAZ housekeeping gene expression. The red dotted line is set at 1.0-
fold (no change). (b) Ploidy distributions are not significantly altered by 17p TLN transfection in G2-arrested LIG1-
depleted cells. The bar chart shows separated data for 17p TLN or 0 DNA control transfected L1
-/fx:Cre
 cells harvested 
at 24 hr post-nucleofection. The proportions of cells in each cell cycle phase are colour coded as in Figure 3b and 3c. 
Data for each fraction is plotted as the mean with SD. One-way non- Kruskal-Wallis ANOVA of individual population 
fractions (significance set as alpha = 0.05) indicates no statistically significant differences; P values listed alongside 
relevant populations. 
  
Supplementary Figure 4 
Construction and validation of an HCT116 LIG3
-/-
:LIG4
-/-
 conditional LIG1 deletion cell line. (a) Exon 23 (blue) of 
one LIG1 allele was targeted by CRISPR/Cas9. Flanking Cre recombinase loxP sites (yellow arrowheads) were 
introduced by homology-directed repair following electroporation of a rAAV plasmid donor bearing a silent mutation 
that interrupts the protospacer adjacent motif (PAM) sequence to prevent donor plasmid cleavage by the Cas9 
nuclease. One clone (#15; C15) from 21 screened was identified with one correctly ‘floxed’ allele and one null allele 
with an exon 23 partial 3’ deletion that includes the splice donor for exon 24 (LIG3
-/-
:LIG4
-/-
LIG1
-/flox
). Lentiviral 
integration of Cre-oestrogen receptor (CreERt2) transgene generated a stable conditional LIG1 deletion cell line 
(LIG3
-/-
:LIG4
-/-
LIG1
-/flox:CreERt2
) where excision of the single remaining functional exon 23 is achieved by treatment with 
4-OHT. Two clones (C15-5 and C15-9) were isolated and validated for use in these experiments. The lower panel 
shows a 640 bp sequence window and cartoon depiction (above) of the human LIG1 targeted locus displaying the 
LIG1 sequence replaced by loxP sites (yellow) flanking exon 23 (blue) with CRISPR/Cas9 sgRNA recognition site 
marked with a grey box. Diagnostic primer binding sites for validation of allelic deletion are indicated as purple arrows 
and within the text sequence as purple underlined (LIG1 Ex22_F) or highlighted (LIG1 Int23_R) sequences. GRCh38 
Chr19 genomic positions delineating the start and end of sequence window are indicated in bold. The LIG1 null allele 
created by the initial CRISPR/Cas9 targeting is displayed in (b) aligned with the endogenous LIG1 sequence (WT). 
Exon 23 sequence in blue capitals, intron 23-24 sequence in dark grey lower case, deleted nucleotides represented 
by dashes. The bottom line of sequence shows the continuous null allele sequence resulting from the deletions. (c) (i) 
Diagram of LIG1 allelic recombination outcomes: genomic (WT); ‘floxed’ allele with intact exon 23 (blue) flanked with 
loxP sites (yellow arrowheads); null allele with exon 23 partial deletion (abridged blue exon 23 box); deleted allele 
following 4-OHT-activated Cre recombination of exon 23 flanking loxP sites. (ii) Genomic PCR results obtained using 
primers indicated in (a) to amplify LIG1 locus from LIG3
-/-
:LIG4
-/-
:LIG1
-/flox
 (C15) and LIG3
-/-
:LIG4
-/-
:LIG1
-/flox:CreERt2
 (C15-
5 and C15-9) cells treated with MeOH carrier (-) or 4-OHT (+) for 24 hr. Band signal intensity values for null (N) and 
deleted/’floxed’ (/Fx) allelic ratios (x10
-2
) are listed above the sample lanes. G+; WT HCT116 and H-; water blank 
controls. (iii) Mean relative expression of LIG1 mRNA (Ex22_F and Ex23_R primers) in MeOH- and 4-OHT-treated 
LIG3
-/-
:LIG4
-/-
:LIG1
-/flox:CreERt2
 cells, as determined by RT-PCR and plotted with 95% confidence intervals. Statistical 
significance was assessed by one-tailed paired T-test with P value reported. (d)(i) Genomic PCR results obtained as 
in (c)(ii) in unsynchronised (Noc -) or G2-arrested (Noc +) LIG3
-/-
:LIG4
-/-
:LIG1
-/flox
 (C15) and LIG3
-/-
:LIG4
-/-
:LIG1
-
/flox:CreERt2
 (C15-5 and C15-9) cells treated with MeOH carrier (-) or 4-OHT (+) for 24 hr. Band signal intensity values for 
null (N) and deleted/’floxed’ (/Fx) allelic ratios (x10
-2
) are listed above the sample lanes. G+; WT HCT116 and H-; 
water blank controls. (ii) Prototypical images of unsynchronised or G2-arrested LIG3
-/-
:LIG4
-/-
:LIG1
-/flox
 (C15) and LIG3
-
/-
:LIG4
-/-
:LIG1
-/flox:CreERt2
 (C15-5 and C15-9) cells treated with 4-OHT for 24 hr is shown. Complete field of view images 
with 20X magnification are displayed with a 250 M scale bar. (iii) Changes in mean cell diameter induced by 24 hr 
MeOH (black shapes) or 4-OHT (white shapes) treatment of G2-arrested LIG3
-/-
:LIG4
-/-
:LIG1
-/flox
 (C15) and LIG3
-/-
:LIG4
-/-
:LIG1
-/flox:CreERt2
 (C15-5 and C15-9) cells from 3-5 independent experiments are shown as mean values with 
95% confidence intervals. One-tailed paired T-tests between appropriate samples were performed to test statistical 
significance.   
Supplementary Figure 5 
Fusions amplified from LIG1-depleted LIG3
-/-
:LIG4
-/-
:LIG1
-/flox:CreERt2
 cells are characterised by fragmented 
insertion and inversions. Examples of 21q TLN-induced telomere fusions reamplified from G2-arrested and 4-OHT-
treated LIG3
-/-
:LIG4
-/-
:LIG1
-/flox:CreERt2
 (Clone 15-9) cells and Sanger sequenced are shown in (i)-(iv). The (shorter) 
centromeric and longer (telomeric) components of each fusion are depicted in red and blue, respectively, in 
accordance with Figure 4. The distance of the fusion point from the 21q TLN cleavage site (1.5kb from the start of the 
telomere repeat array) is marked as bp in the appropriate colours. Microhomology at the fusion junction is indicated 
in purple and underlined. Insertions are depicted in green and localised templated duplications are in italics and 
underlined. Fusion sequence (iv) illustrates complex template switching within a genomic context resulting from a 
fusion with the 16p subtelomere cleaved by the 21q TLN within 1 kb of the telomere repeat array. Fragments of the 
BCL9L gene on chromosome 11 annealed in opposing orientations are marked in orange and brown and // indicates a 
break in the alignment. 
Supplementary Table 1 
Primers used in this study 
Primer name Primer sequence 5′ to 3′ Target gene symbol Assay usage cDNA amplicon 
size 
gDNA amplicon 
size 
Annealing 
temperature 
(Tm) °C 
YWHAZ_F TTCTTGATCCCCAATGCTTC YWHAZ RT-PCR 211 bp 828 bp 60 
YWHAZ_R AGTTAAGGGCCAGACCCAGT YWHAZ RT-PCR 211 bp 828 bp 60 
LIG1_Ex4_F GGAAGAGGAGGATGAAGCCC LIG1 RT-PCR 161bp 4392bp 60 
LIG1_Ex5_R GACGCTTCGGAATCCTGAT LIG1 RT-PCR 161bp 4392bp 60 
LIG1_Ex17_F GAATTATCCCCGTGCTGCT LIG1 RT-PCR 254bp 2947bp 65 
LIG1_Ex19_R CGGGTACTTCCCAGTGTTGT LIG1 RT-PCR 254bp 2947bp 65 
LIG1_Ex22_F CTGGTACGTGAGCCCCTTT LIG1 RT-PCR 221 bp 378 bp 60 
LIG1_Ex23_R AGCCAGTTGTGCGATCTCTT LIG1 RT-PCR 221 bp 378 bp 60 
LIG3_F AGGCAGCAGGTACACCAAAG LIG3 RT-PCR 235 bp 3569 bp 60 
LIG3_R TCCCGTAGCAGACAGTCCTT LIG3 RT-PCR 235 bp 3569 bp 60 
LIG4_F CCGAGGCCAGTTAAACGAG LIG4 RT-PCR 287 bp 3528 bp 60 
LIG4_R TCCATAGGCCATTCTCTCTCT LIG4 RT-PCR 287 bp 3528 bp 60 
DPP4_F CAGCTGACAGTCGCAAAACT DPP4 RT-PCR 229 bp 1926 bp 60 
DPP4_R TGCCCATCAGGAGATATTGA DPP4 RT-PCR 229 bp 1926 bp 60 
HMGA2_F ACTTCAGCCCAGGGACAAC HMGA2 RT-PCR 180 bp 13229 bp 60 
HMGA2_R TCCAGTGGCTTCTGCTTTCT HMGA2 RT-PCR 180 bp 13229 bp 60 
CDKN1A_F GCGACTGTGATGCGCTAAT CDKN1A RT-PCR 400 bp 1603 bp 60 
CDKN1A_R TAGGGCTTCCTCTTGGAGAA CDKN1A RT-PCR 400 bp 1603 bp 60 
IL6_F TACCCCCAGGAGAAGATTCC IL6 RT-PCR 175 bp 1232 bp 60 
IL6_R TTTTCTGCCAGTGCCTCTTT IL6 RT-PCR 175 bp 1232 bp 60 
LIG1_LOXP_SF ATGTCCTGTTCGCCTCAC LIG1 Genomic PCR NA WT:563 bp 
Floxed:698 bp 
Deleted:448 bp 
60 
LIG1_LOXP_SR2 AGGGTACACAGTGGAGTC LIG1 Genomic PCR NA WT:563 bp 
Floxed:698 bp 
Deleted:448 bp 
60 
LIG1 Ex22_F CTGGAGCAGTCAGTGAAAGG LIG1 Genomic PCR NA WT:464 bp 
Floxed:503 bp 
Deleted:260 bp 
60 
LIG1 Int23_R GGCTGTTCTCCATCAGAACTC LIG1 Genomic PCR NA WT:464 bp 
Floxed:503 bp 
Deleted:260 bp 
60 
17p6 GGCTGAACTATAGCCTCTGC 17p subtelomere Telomere fusion PCR NA NA 62 
XpYpM ACCAGGTTTTCCAGTGTGTT  XpYp subtelomere Telomere fusion PCR NA NA 62 
21q1 CTTGGTGTCGAGAGAGGTAG 21q family subtelomere Telomere fusion PCR NA NA 62 
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19: 48123673
19: 48122709
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∆1866bp
∆336bp
GTACAAAGATGGAAGATAACTTCATTGAAAATATATACCAGGTGTGCTATCTTTTTGTGGTTTTCATTTCTCTA
∆1823bp
∆300bp
21q-21q asymmetric inverted fusion with microhomology(ii)
21q-21q asymmetric fusion with microhomology(i)
AGCCACGACAATGCCAGCAAGAGGGCCCGGCACTGTGCCCAGCTACCTCTCTCGACACCAAG
∆35bp
∆2136bp
∆2156bp
∆82bp
16p-Chr11 inverted fragmented fusion(iv)
21q-21q inverted fragmented fusion with microhomology, insertions and duplications(iii)
∆342bp ∆353bp
∆1844bp ∆1601bp
∆605bp ∆796bp
∆1105bp ∆300bp
GTAAAGAGCTTATTTTGTGGTT...TCTCTTCCACCATCATACCATACCAGG...ATGATGATTGGGGCATCTCAAGAGAAGTTC
∆1781bp
GTCGATGGCACCTGACTGCA..GACATGTT//CTCCGCATG...CACCCACA//GAAACACA...GGGAAGT//CAGTGTCCCCGAG
Chr11:118920873-929
Chr11:118922527-479 Chr11:118922039-21955
Chr11:118921181-504
microhomology
microhomology
microhomology
insertion
